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The Role of A2BR Signaling in Adenosine Dependent Lung Disease
Publication No. _________________
Yang Zhou, B.S.
Supervisory Professor: Michael R. Blackburn, Ph.D.

Chronic lung diseases and acute lung injuries are two distinctive
pulmonary disorders that result in significant morbidity and mortality. Adenosine
is a signaling nucleoside generated in response to injury and can serve both
protective and destructive functions in tissues and cells through interaction with
four G-protein coupled adenosine receptors: A1R, A2AR, A2BR, and A3R.
However, the relationship between these factors is poorly understood. Recent
findings suggest the A2BR has been implicated in the regulation of both chronic
lung disease and acute lung injury. The work presented in this dissertation
utilized the adenosine deaminase-deficient mouse model and the bleomycininduced pulmonary injury model to determine the distinctive roles of the A2BR at
different stages of the disease. Results demonstrate that the A2BR plays a
protective role in attenuating vascular leakage in acute lung injuries and a
detrimental role at chronic stages of the disease. In addition, tissues from
patients with chronic obstructive pulmonary disease and idiopathic pulmonary
fibrosis were utilized to examine adenosine metabolism and signaling in chronic
lung diseases. Results demonstrate that components of adenosine metabolism
and signaling are altered in a manner that promotes adenosine production and
signaling in the lungs of these patients. Furthermore, this study provides the first
evidence that A2BR signaling can promote the production of inflammatory and
fibrotic mediators in patients with these disorders. Taken together, these findings
suggest that the A2BR may have a bi-phasic effect at different stages of lung
disease. It is protective in acute injury, whereas pro-inflammatory and pro-fibrotic
at the chronic stage. Patients with acute lung injury or chronic lung disease may
both benefit from adenosine and A2BR-based therapeutics.
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CHAPTER 1
INTRODUCTION
Chronic lung diseases are featured by processes such as inflammation
and tissue remodeling that contribute to a progressive pulmonary function
decline. The prominent and deadly features in these disorders make them the
third leading cause of death in the US following cancer and cardiovascular
disease. Acute lung injury and acute respiratory distress syndrome contribute
significantly to critical illness. Although chronic lung diseases and acute lung
injuries exhibit distinct molecular basis and pathogenesis, they both result in
significant morbidity and mortality and some overlapping features are observed in
these disorders. Studies are needed to investigate the mechanisms involved in
disease progression and the similarities and differences between these
disorders.

Chronic Lung Disease and Acute Lung Injury
Chronic lung disease describes pulmonary disorders where persistent
inflammation and structural alternation contribute to progressive loss of lung
function (1). Examples of chronic lung disease include asthma, chronic
obstructive pulmonary disease (COPD) and interstitial lung disease. Asthma is
characterized by episodic airway obstruction, airway hyperresponsiveness,
cellular infiltration, mucus hypersecretion and airway remodeling (2, 3). COPD is
accompanied by chronic bronchitis and emphysema (4), while interstitial lung
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diseases exhibit varying degrees of airway fibrosis and inflammation (5, 6).
These lung diseases afflict numerous individuals and result in hundreds of
thousands of dollars in annual health costs. Currently there are no effective
treatments, especially during the chronic phase of these diseases. The
inflammatory response seen in these disorders involves the recruitment of
multiple types of inflammatory cells and results in the release of a number of
soluble mediators that drive inflammation and remodeling processes in the lung
(7, 8). Although the mechanisms responsible for the genesis of inflammation and
the regulation of tissue remodeling have been well established, relatively little is
described about the signaling pathways that serve to regulate the progressive
and chronic nature of these diseases (9).
A normal wound healing response is involved in chronic lung diseases.
For example, collagen deposition, epithelial cell remodeling and angiogenesis
around the bronchial airways are characteristic features in asthma. Interstitial
lung diseases are featured by fibroblast proliferation and extensive extracellular
matrix deposition, whereas imbalances in matrix proteases and anti-proteases
and destruction of the alveolar airways are often observed in patients with
COPD. It has been suggested that the excessive tissue remodeling processes
that are observed in chronic lung diseases result from overactive or deregulated
wound healing pathways (2, 10). Efforts targeted at understanding the molecular
pathogenesis of these diseases and how the diseases progress will lead to better
treatment options and decreased mortality.

2

Acute lung injury and acute respiratory distress syndrome can develop in
a number of different clinical conditions such as pneumonia, acid aspiration,
major trauma, or prolonged mechanical ventilation (11). Experimental and clinical
studies have demonstrated that the pathogenesis of TH1 inflammation and acute
lung injury are characterized by pulmonary trafficking of polymorphonuclear
leukocytes (PMNs) into the lungs (12). Activation of circulating PMNs initiates the
recruitment of leukocytes to the lung (13). Transendothelial migration and
transepithelial migration into the lung interstitium and into the alveolar space are
initiated following PMNs adherence to the pulmonary vessel wall. Enhanced
inflammation and damage is associated with enhanced permeability of
microvasculature, thus pulmonary vascular barrier function serves as a protective
barrier in acute stages of injury (14, 15). However, the molecular mechanisms
underlying PMN trafficking in the lung is not fully understood. Better
understanding the substantial mechanisms of PMN migration into the tissue in
ALI and ARDS-typical symptoms, including the regulation of microvascular
permeability, expression of adhesion molecules, release of cytokines and
chemokines, will help prevent or treat these acute injuries (16, 17).

Adenosine Metabolism and Signaling
Adenosine is a signaling molecule that is generated at sites of organ
damage and tissue injury and is therefore increased during tissue hypoxia and
inflammation (18). ATP is released into the extracellular space, where it is quickly
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Figure 1
Adenosine metabolism and signaling. In response to cellular stress and
damage, ATP is released into the extracellular space and is rapidly
dephosphorylated by extracelluar nucleotidases. CD73 catalyzes the formation
of extracellular adenosine from AMP. Extracellular adenosine can interact with
seven-transmembrane adenosine receptors, A1R, A2AR, A2BR, and A3R, which
are coupled by heterotrimeric G proteins to various second messenger
systems, or it can be transported into cells via facilitated nucleoside
transporters, such as ENT1. Both extracellular and intracellular adenosine can
be deaminated to inosine by adenosine deaminase (ADA). Intracellular
adenosine can be secreted or phosphorylated back to ATP. The first step in
this process is catalyzed by adenosine kinase (AK).
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dephosphorylated by extracellular nucleotidases to form extracellular adenosine
(19). Adenosine can enter cells via facilitated nucleoside transporters, or function
on cells by interacting with G protein coupled adenosine receptors (20). Both
extracellular adenosine and intracellular adenosine can be deaminated to inosine
by the enzyme adenosine deaminase (ADA) (21) (Figure 1). Adenosine has
potent anti-inflammatory as well as pro-inflammatory functions (22). Expression
profiles of specific adenosine receptors on specific organs and cells likely
mediate the distinct pro- and anti-inflammatory roles of adenosine (18). Four
adenosine receptors have been identified: A1R, A2AR, A2BR and A3R. These
receptors have a seven membrane-spanning structure and are coupled to
heterotrimeric G proteins. Each adenosine receptor has a unique affinity and a
distinct cellular and tissue distribution (20, 23). Adenosine receptor signaling can
influence cellular physiology through a variety of mechanisms and access
multiple intracellular signaling pathways (24). A1R and A3R are coupled to
inhibitory G proteins and can downregulate adenyl cyclase activity to decrease
cAMP levels, while A2AR and A2BR are coupled to stimulatory G proteins and
increase cAMP levels. In addition, adenosine receptors are coupled to other
signaling molecules such as Phospholipase C, PI3K and MAPKs.
Adenosine plays distinctive roles in chronic versus acute lung injuries. In
chronic lung diseases, elevations in adenosine are found in these patients (25)
and inhaled adenosine and/or its precursor AMP elicit bronchoconstriciton in
asthmatics and COPD patients (26). Adenosine is generated following injury and
it can promote processes that are critical in wound healing such as angiogenesis,
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matrix production and the regulation of inflammation. An A2AR agonist can
increase the rate of wound healing by increasing the production of extracellular
matrix and angiogenesis (27). A2AR and A2BR activation promotes fibroblast
differentiation and matrix production (28-30). It also results in VEGF production
(31), endothelial cell proliferation (32), and granulation tissue formation, thus
leading to angiogenesis (33). In addition, the engagement of adenosine receptors
influences mast cell degranulation (34), eosinophil function (35) and stimulates
mucus production by airway epithelium (36). These findings suggest that
adenosine signaling can influence cellular events in chronic lung diseases and
adenosine is suggested to play an important role in regulating the chronic nature
of asthma and COPD. Whereas it appears that adenosine plays a largely
detrimental and tissue-destructive role in the regulation of chronic lung disease,
substantial evidence suggests that extracellular adenosine signaling plays
important anti-inflammatory roles in acute lung injury through engaging its
receptors. During acute injuries, adenosine is generated in extracellular space to
regulate the acute inflammatory response. CD39 and CD73 are the enzymes that
coordinate a two-step conversion of adenosine from its precursors. It has been
shown that CD39 and CD73 levels are elevated in the lungs following LPS
stimulation and neutrophil accumulation was enhanced in mice treated with
inhibitors of these enzymes and in CD39 and CD73-deficient mice (17, 37). In
addition, numerous genetic and pharmacologic antagonism studies have
identified specific adenosine receptors involved in tissue protection in various
acute injury models such as LPS induced injury (38), ventilator-induced lung
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injury (39), hypoxia-induced injury (14), and ischemia reperfusion injury (40-44).
Because of the diverse effects of adenosine and its receptors, extensive
research has been dedicated to developing potential therapeutics targeting
adenosine metabolism and signaling.

Adenosine Deaminase-deficient Mouse Model
A mouse model of adenosine-mediated pulmonary injury has been
developed in our lab and it has allowed us to examine the consequences of
adenosine elevations on pulmonary inflammation and tissue remodeling. The
purine catabolic enzyme, ADA, decreases the levels of adenosine as well as
deoxyadenosine in tissues and cells. Genetic removal of ADA results in a
significant elevation of concentrations of these substrates systemically. A severe
combined immunodeficiency is observed in ADA-deficient mice because of the
accumulation of deoxyadenosine in the thymus and spleen (45, 46), while
adenosine accumulations result in the development of pulmonary inflammation
and lung architecture remodeling, features consistent with various aspects of
chronic lung disease seen in human. ADA-deficient mice spontaneously develop
signs of respiratory distress and progressive pulmonary injury characterized by
increases in activated alveolar macrophages, enlargement of alveolar space,
mucus production in bronchial airways, and airway hyperresponsiveness. They
also develop subepithelial fibrosis and extracellular matrix deposition, features
consistent with interstitial lung diseases (47, 48). In addition, there is an upregulation in levels of cytokines and pro-inflammatory mediators commonly
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elevated in association with asthma and COPD including serum IgE and TH2
cytokines (47, 49), mediators of airspace enlargement such as matrix
metalloproteases and cathepsins (49). These features are seen in patients with
chronic lung diseases and are related to increases in lung adenosine levels.
Additional evidence suggesting that the phenotypes seen in ADA-deficient
mice are directly mediated by adenosine levels is seen through the use of
exogenous ADA enzyme therapy. ADA covalently linked to polyethylene glycol
(Peg-ADA) was used to treat ADA-deficient mice and prevented or reversed
many aspects of the pulmonary phenotype (45, 50). If ADA-deficient mice are
kept on PEG-ADA enzyme therapy from birth, the phenotype is completely
prevented allowing normal development and life span. In addition, ADA enzyme
therapy can be used to treat ADA-deficient mice even after they have established
severe pulmonary phenotypes, thus reversing pulmonary injury. These findings
display a clear correlation between adenosine levels, its contribution to the
overall morbidity in this model, and the presence of lung pathology. The ADAdeficient mouse model and the use of ADA enzyme therapy provide us a great
system to characterize the role of adenosine in the pathology of chronic lung
diseases.

A2B Adenosine Receptor
The A2BR is widely expressed in tissues and cells and has the lowest
affinity for adenosine (20). It has been shown that all cell types in the lung
express A2BR transcripts and the levels of expression increase in inflammatory
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environments. It is generally accepted that A2BR is coupled to Gs proteins to
activate adenyl cyclase and increase cAMP levels (51, 52). In addition, regulatory
proteins of the Gq family are thought to play a role in the coupling of A2BRs to
phospholipase C (PLC) in human mast HMC-1 cells (53). A2BR activation has
both anti-inflammatory and pro-inflammatory actions and both pro- and antifibrotic roles (54). Numerous studies have shown that the A2BR has tissue
destructive functions in that the engagement of the A2BR can promote the
differentiation of pulmonary fibroblasts into myofibroblasts and hence increase
the deposition of collagen and fibrosis (30). Engagement of the A2BR can
mediate the direct expression of pro-inflammatory cytokines such as IL-8, IL-4
and IL-13 from human HMC-1 cells (53, 55) and mouse mast cells (56).
Consistent with this, treatment of ADA-deficient mice with an A2BR antagonist
resulted in diminished pulmonary inflammation and fibrosis (57). In contrast to
these results, recent observations usinig A2BR knockout mice suggest that the
ablation of the A2BR causes low-grade inflammation and enhanced leukocyte
adhesion to the vasculature (58). In addition, the deletion of this Gs-coupled
receptor on mouse bone marrow-derived mast cells leads to decreased levels of
cAMP and enhances mast cell activation (59). Moreover, it is proposed that A2BR
signaling is responsible for the phosphorylation of vasodilator-stimulated
phosphoprotein, which controls the geometry of actin-filaments and mediates
junctional protein distribution, thereby promoting increases in endothelial barrier
functions by affecting the characteristics of the endothelial junctional complex (3).
Clearly, discrepancies exist when investigating the roles of the A2BR. These
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findings suggest that engagement of the A2BR is complex and additional studies
are needed in order to clarify the A2BR’s multiple inflammatory and remodeling
roles during the course of injury and repair.

Dissertation Overview
The overall aim of this dissertation is to better understand the role of the
A2B adenosine receptor in pulmonary disease. To accomplish this goal, I have
utilized two animal models to characterize A2BR’s role from different aspects and
at different stages of lung disease. In Chapter 3, I characterized the phenotypes
in ADA/A2BR double knockout mice to study the contribution of this receptor in
adenosine dependent lung injury. Based on a previous receptor antagonism
study shown that the A2BR plays a tissue-destructive and pro-fibrotic role, I
hypothesized that the genetic removal of the A2BR from ADA-deficient mice
would lead to enhanced pulmonary injury and damage. Unexpectedly, lack of the
A2BR in ADA-deficient mice resulted in loss of vascular barrier functions and
ADA/A2BR double knockout mice showed enhanced pulmonary phenotypes
compared to ADA-deficient mice (60). I then hypothesized that the A2BR may play
a homeostatic and protective role in regulating vascular barrier function during
the early or acute stage of pulmonary injury, while a tissue-destructive and profibrotic role at the chronic stage of the disease. In Chapter 4, I utilized an animal
model of pulmonary fibrosis to directly investigate the bi-phase role of A2BR at
different stages of lung injury. Finally, in Chapter 5, I utilized specimens from
patients with chronic lung disease to further investigate the roles of the A2BR in
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human disease. I hypothesized that adenosine metabolism and signaling are
altered in human diseases. My findings suggest that A2BR signaling pathways are
enhanced in severe diseases and that these pathways play important roles in
exacerbating disease status.
The findings in this dissertation raise the possibility that adenosine-based
therapeutics may be beneficial in the treatment of chronic lung diseases. They
also suggest that A2BR signaling has important anti-inflammatory activities during
early stages of lung disease that were revealed by the global genetic removal of
the A2BR, whereas A2BR engagement during active disease may contribute to
disease progression. As the A2BR antagonist is under phase II clinical trials to
treat chronic lung disease, these findings are particularly timely and important.
Our findings suggest that the stage of disease and the degree of A2BR
antagonism or agonism will be critical variables to assess when using A2BR
based therapeutics in the treatment of lung diseases. Overall, these studies
provide novel insight into the role of the A2BR in pulmonary disease and will aid in
the development of novel therapies.
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CHAPTER 2
EXPERIMENTAL PROCEDURES

Generation and Genotyping of Mouse Lines
ADA-deficient mice were generated and genotyped as previously
described (46). Mice homozygous for the null Ada allele were designated ADAdeficient (ADA-/-). Mice heterozygous for the null Ada allele were designated as
control mice (ADA+). ADA/A2BR double knockout mice were generated by mating
ADA-/- mice with A2BR-deficient mice (A2BR-/-). Mice were congenic on C57BL/6
background, and phenotypic comparisons were conducted among littermates.
Animal care was in accordance with NIH guidelines and the Animal Care
Committee at the University of Texas Health Science Center at Houston. All
animals were housed under strict containment protocols and maintained in
ventilated cages equipped with microisolator lids. Serologies on cage littermates
were negative for 12 of the most commonly seen viruses in mice. No evidence of
fungal, parasitic, or bacterial infection was found.

ADA Enzyme Therapy
Polyethylene glycol modified-ADA (PEG-ADA) was generated by the
covalently linking purified bovine ADA with activated polyethylene glycol (45).
ADA-/- mice were injected intramuscularly with Peg-ADA on postnatal days 1, 5,
9, 13, 17(0.625, 1.25, 2.5, 2.5 and 2.5 units, respectively) and intraperitoneal
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injections on postnatal day 21 (5 units). Animals were sacrificed on postnatal day
35 (14 days after the last Peg-ADA injection).

Bronchial Alveolar Lavage and Histology

Avertin was used to anesthetize the animals, and airways were lavaged 4
times with 0.3 ml PBS; about 1 ml of pooled lavage fluid was able to be
recovered. Total cell numbers were determined by counting on a hemocytometer.
Cellular differentials were determined by cytospining BAL aliquots onto
microscope slides and staining with Diff-Quick (Dade Behring) for. After lavage,
the lungs were inflated with 10% buffered formalin phosphate in PBS at 25 cm of
pressure and then fixed at 4°C overnight. Formalin-fixed lungs were dehydrated
in ethanol gradients, and then paraffin embedding was performed. 5 μm tissue
sections were cut and collected on microscope slides and stained with H&E
(Shandon-Lipshaw) according to manufacturer’s instructions.

Immunostaining on Mouse Lung Sections
Rehydrated slides were quenched with hydrogen peroxide (3%), followed
by antigen retrieval for 30 min at 95°C (Dako Corp.), and endogenous avidin and
biotin blocking was performed with a Biotin Blocking System (DAKO Corp.).
Slides were incubated with Rat Anti-mouse Neutrophils Antibody (AbD SeroTec,
1:500 dilution, overnight at 4°C). ABC Streptavidin reagents and individual
appropriate secondary antibodies were used to incubate lung sections, and then
lung sections were developed with 3, 3'-diaminobenzidine (Sigma-Aldrich) and
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methyl green counterstaining was performed. Slides were coversliped with
Vectashield (Vector Laboratories) mounting medium.

Airspace Size Measurement

Mean chord lengths on H&E-stained lung sections cut from a constantpressure infused lungs were used to determine the average alveolar airspace
size (47). Representative images were captured, and overlaid with a grid
consisting of 53 black lines at 10.5-μm intervals. This line grid was subtracted
from the lung images using Image-Pro Plus image analysis software (Media
Cybernetics), and the mean chord length of the alveolar airspaces were
determined by measuring and averaging the resultant lines. 10 non-overlapping
images of each lung were used to determine the final average mean chord
lengths.

TUNEL Analysis
ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit (Chemicon) was
used and end labeling of exposed 3′-OH ends of DNA fragments in paraffinembedded tissue was undertaken under the instructions provided by the
manufacturer. After staining, in each section a minimum of 300 positive-labeled
cells were evaluated visually. The amount of positive-labeled cells was
expressed as a percentage of total nuclei evaluated.
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RT-PCR and Quantitative RT-PCR
Whole lung RNA was extracted from frozen lungs using Trizol reagent
(Invitrogen Corp.). RNA samples were digested with RNase-free DNase-1
(Invitrogen Corp.). A Superscript One-Step RT-PCR (Invitrogen Corp.) reaction
with β-actin or A2BR specific primers were performed using lung RNA (1μg)
following the manufacturer’s instruction. Real-time quantitative RT-PCR was
performed to quantitate transcript levels. Smart Cycler (Cepheid) was used to
determine A2BR and β-actin transcripts using Taqman probes. Cytokine and
chemokine transcripts were analyzed using SYBR Green method or Taqman
probes on the Smart Cycler RT-PCR machine (Cepheid). Primer sequences
were the same as previously used for the transcripts examined (47, 48, 57, 61,
62). Specific gene transcript levels were calculated either by generating a
standard curve from template dilutions and the PCR amplification, or 18S
ribosomal RNA was used an a normalizer and the comparative Ct method (2∆∆Ct)
was used to present the data as mean normalized transcript levels (63).

Western Blot Analysis
Frozen lungs samples were homogenized and lysed on ice with protein
lysis buffer (1M Tris pH7.4, 1M NaCl, 1% Triton-X 100) containing 1× protease
inhibitor cocktail (Roche Diagnostics). After vortexing the lysates vigorously,
lysates were cleared by centrifugation at 14,000rpm for 15 min at 4°C.
Electrophoresis was performed using 50 micrograms/sample of total protein on
10% SDS-PAGE gels and transferred overnight at 4°C to Immobilon-P PVDF
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membranes (Millipore), and Western blotting analysis was performed as
previously described (64). The following antibodies were used: rat monoclonal
anti-E-selectin antibody (R&D Systems; 1:5,000 dilutions), rabbit polyclonal antiICAM-1 antibody (Santa Cruz Biotechnology.; 1:200 dilution), rabbit monoclonal
anti-IκB-α antibody (abcam; 1:5,000 dilution), mouse monoclonal anti-β-actin
antibody (Sigma-Aldrich; 1:5,000 dilution). Secondary antibodies are: anti-rabbit
IgG-HRP (eBioscience; 1:10,000 dilution), anti-mouse IgG-HRP (eBioscience;
1:10,000 dilution), and anti-rat IgG-HRP (Sigma-Aldrich; 1:10,000 dilution).
Chemiluminesce signal were detected (Pierce).

Cytokine and Chemokine Analysis
The levels of the cytokines IL-1α, IL-1β and the chemokines CXCL-1,
MCP-1, LIF, RANTES and MIG were examined. Blood was collected using EDTA
as an anticoagulant. The blood was centrifuged at 1,200rpm for 20 min to obtain
plasma. BAL fluid was collected as described previously and was centrifuged to
remove cells. Plasma and the BAL fluid supernatants were then used to
quantitate the amount of these cytokines and chemokines by using the Milliplex
mouse cytokine/chemokine panel (Millipore) per the manufacturer’s instructions.

Measurement of Vascular Permeability
BAL fluid was collected as previously described and was centrifuged to
remove cells. BAL fluid supernatants were then used to determine total protein
content by Bradford Assay (BioRad). To assess pulmonary edema, lungs (n = 6)
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were weighed and dried. Weight ratios before and after drying were used to
determine lung water content. Organ vascular permeability was quantified by
intraperitoneal administration of Evans blue dye (0.2 mL of 0.5% in PBS).
Circulation was perfused with PBS and the heart and lung were harvested four
hours after the dye injection. After formamide extraction (55°C Overnight), organ
Evans blue concentrations were quantified by measuring absorbances at 610 nm
with subtraction of reference absorbance at 450 nm. The contents of Evans blue
dye were determined by generating a standard curve from dye dilutions.

Mucus index

Periodic acid-Schiff (PAS)-staining was performed and the amount of
produced mucus in bronchial airways was calculated by determining the amount
of PAS positively labeled material using Image-Pro Plus analysis software (Media
Cybernetics). PAS-positive areas were identified and separated on digitized
images, and the averaged intensities of pixel of each color channel (red, blue,
and green) were calculated. After repeating the same procedure for each image,
the average values were used to calculate the area (M) and intensity (I) of PASstained material in major and bronchial airways. In addition, the area (A) of the
total epithelium (including both PAS-negative and positive areas) was
quantitated. The equation (M x I)/A was used to determine the mucus index.
Averages of 10 pictures from each lung including both small and large bronchial
airways were used to determine the final indices. All quantitative studies were
performed blinded.
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Whole Mount Immunohistochemistry for CD31 on Tracheas

Whole mount immunohistochemistry on tracheas were performed as
described previously (65). Tracheas were cut and removed from mice and then
washed with cold PBS. Insect pins onto silicone polymers were used to flatten
tracheas after removing surrounding tissues. PBS was used to wash tracheas for
10 min and the zinc fixative (BD Pharmingen) was used to fix tracheas at least
overnight. 3 PBS washes for 5 min per wash were performed after fixation. PBS
containing 1% Triton X-100 was then used to permeabilize tracheas for 300 min
were. 0.6% hydrogen peroxide was used to block endogenous peroxidase
activity by incubating tissues for 30 min. Then Immunohistochemistry for CD31
was conducted with an anti-rat Ig horseradish peroxidase detection kit (BD
Pharmingen) according to the manufacturer's instructions. Tissues were
incubated overnight with a 1:250 dilution of rat anti-mouse CD31 antibody (BD
Pharmingen). Permount (Fisher) was then used to mount the tissues after
dehydration.

Quantification of BAL Fluid Adenosine Levels

Mice were anesthetized with avertin, and lungs were lavaged 4 times with
0.3 ml PBS containing 2μM dipyridamole and 5μM DCF; 0.95-1 ml of pooled
lavage fluid was recovered. Adenosine was separated and quantified using
reverse-phase HPLC.
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Intratracheal Bleomycin Treatment
Avertin (250 mg/kg, intraperitoneally) was used to anesthetize 10-week
old female wild type or A2BR-/- mice, and saline alone or 2.5 U/kg bleomycin
(Teva Parenteral Medicines, Inc. Irvine, CA) diluted in 50 µl sterile saline was
instilled intratracheally. Endpoints were examined at 7 and 21 days after
challenge.

Intraperitoneal Bleomycin Treatment
6-week old male WT or A2BR-/- mice were treated with 0.035 U/g
bleomycin (Teva Parenteral Medicines, Inc. Irvine, CA) diluted in 150 µl sterile
PBS or PBS alone intraperitoneally. Mice were treated twice weekly for 4 weeks
and were weighed and sacrificed on day 33. Endpoint at day 10 was also
examined after 3 injections.

Fibrosis Assessment
The Sircol assay (Biocolor Ltd., Carrick, UK) was used to quantitate
soluable collagen levels in BAL fluid. Ashcroft scores were determined on H&Estained lung sections. Twenty fields per section were used to determine the
Ashcroft score blinded. 4 mice per group for controls and 6 mice per group for
Bleomycin-treated mice were examined.
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Human Subjects
Deidentified human open lung biopsy tissue samples were obtained from
the Lung Tissue Research Consortium (LTRC) (Table 2.1). Patients were
classified as Stage 0 COPD, Stage 4 COPD, Mild IPF and Severe IPF according
to spirometry, pathological specimen and high resolution CT scan. Stage 0
COPD and Mild IPF patients with preserved lung functions were used as controls
in comparison to Stage 4 COPD and Severe IPF patients. For ex vivo culture
experiments, macrophages were isolated from lavage fluid collected from Stage
4 COPD or Severe IPF patients that were lavaged as part of routine diagnostic
procedures.

Quantitative RT-PCR for Human Samples
Tissue RNA was isolated from frozen lung tissue using Trizol reagent
(Invitrogen Corp.). RNA was purified through an RNA-purification column
(Qiagen) and treated using RNase-free DNase (Invitrogen Corp.). Transcript
levels were quantified using Taqman real-time quantitative RT-PCR. Primer
sequences for the transcripts examined are found in Table 2.2. Specific transcript
levels were determined through comparison to a standard curve generated from
the PCR amplification of template dilutions, and normalized to 18S ribosomal
RNA and presented as mean transcript levels %18s RNA.
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Table 2.1 Study Population
Parameter

Stage 0 COPD1

Mild IPF2

N
4
10
Age, yrs
69 (61-78)
60 (50-77)
Sex, M/F
1/3
6/4
Pack-yrs smoking 25 (25-50)a
8 (3-10)b
Smoking status
Ever/Never
4/0
5/4e
FEV1, % pred 86 (84-89)
92 (66-109)
FVC, % pred 107 (80-113) 89 (80-105)
FEV1/FVC, % 60 (50-80)
80 (60-90)

Stage 4 COPD3

Severe IPF4

10
50 (44-63)
6/4
36 (1-120)c

10
54 (26-62)
7/3
20 (3-32)d

10/0
20 (12-40)*
54 (13-77)*
30 (20-60)*

4/5e
38 (30-46)#
38 (25-43)#
90 (70-100)

Data are presented as median (interquartile range). M/F: male/female; FEV1:
forced expiratory volume in one second; % pred: % predicted; FVC: forced vital
capacity. 1: Stage 0 COPD is defined as FEV1, % pred > 80; 2: Mild IPF is
defined as FVC, % pred > 80; 3: Stage 4 COPD is defined as FEV1, % pred < 50;
4
: Severe IPF is defined as FVC, % pred < 50; a: data available for 3/4 Stage 0
COPD patients; b: data available for 5/10 Mild IPF patients; c: data available for
9/10 Stage 4 COPD patients; d: data available for 4/10 Severe IPF patients; e:
data available for 9/10 Mild or Severe IPF patients. *: p<0.05 compared with
Stage 0 COPD patients; #: p<0.05 compared with Mild IPF patients.
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Table 2.2 Primer pairs and internal probe sequences
Gene

Accession Number

Sequences

CD73 NM_002526

1447+GACAGAGTAGTCAAATTAGATG
1511-TGAGAGGGTCATAACTGG
1471+FAM TCTTTGCACCAAGTGTCGAGTGC

ADA

NM_000022

264+CTGCTGAACGTCATTGG
340-GCAGGCATGTAGTAGTC
281+FAM CATGGACAAGCCGCTCACCC

NM_006721

1092+CCACTATGCAGCAAGCATC
1156-GGAAGTCTGGCTTCTCAGG
112+FAM
TAATTAGACGGACTGGCTGCACCTT

AK

ENT1 NM_001078177

1413+CCAGCCGTGACTGTTGAG
1489-CAGGACACAGGAATGAAGTAAC
1438+FAM CCAGCATCGCAGGCAGCAGC

A1R

NM_000647

1147+GCTGGCTGCCTTTGCAC
1215-GGATGCTGGGCTTGTGG
1165+FAM
TCCTCAACTGCATCACCCTCTTCTGC

A2AR

NM_000675

838+ATGCTGGGTGTCTATTTGCG
902-TGGCTCTCCATCTGCTTCAG
865+FAM CTGGCGGCGCGACGACA

A2BR

NM_000676

977+CACTGAGCTGATGGACCACTC
1040-CAGTGACTTGGCTGCATGG
1018-FAM TCCCGCTGGAGGGTGGTCCT

NM_000677

708+CCCTACAGACGGATCTTGCTG
777-TGTTGGGCATCTTGCCTTC
734+FAM CCTGTCCCTGTGGAGGTTCCCCT

IL-6

NM_000600

153+ CCCCCAGGAGAAGATTCCA
223- TCAATTCGTTCTGAAGAGGTGAG
173+FAM 223TCAATTCGTTCTGAAGAGGTGA

IL-8

NM_000584

100+TCTTGGCAGCCTTCCTGA
182-GCACTGACATCTAAGTTCTTTAGCACT
121+FAM CTGCAGCTCTGTGTGAAGGT

OPN

NM_000582

619+GGACTGAGGTCAAAATCTAAGAAG
693-GGTGATGTCCTCGTCTGTAG
646+FAM CGCAGACCTGACATCCAGTACCCT

A3R
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Enzyme Activity Assay
Lungs were homogenized and lysed on ice with protein lysis buffer (50mM
Tris pH7.4, 150mM NaCl, 1% Triton-X 100, 0.1%SDS, 0.5% Na Deoxycholate)
freshly supplemented with 1× protease inhibitor cocktail (Roche Diagnostics).
Lysates were vigorously vortexed and cleared by centrifugation at 14,000rpm for
15 min at 4°C. To quantify CD73 enzyme activity, 5 µg protein extracts were
incubated with with 100 µM AMP at 37°C for 30 min in the presence of 1 µM
deoxyconformycin in HEPES buffer, with or without 100 µM CD73 inhibitor
adenosine- 5'- O- (α, β- methylenediphosphate) (AOPCP). To quantify ADA
enzyme activity, 10 µg protein extracts were incubated with with 0.2 mM
adenosine at 37°C for 60 min in HEPES buffer with or without 1 µM
deoxyconformycin. Heat-inactive protein extracts were used as negative controls.
Reactions were terminated at 95 degree for 5 min. Reaction mixtures were then
analyzed by reversed-phase (C18) HPLC which permitted direct separation,
identification, and quantitation of enzymatic products (45). Enzyme specific
activity is given as nmol product formed per min per mg protein (nmol/min/mg
protein).

Histology and Immunostaining of Human Lung Sections
HOPE or paraformaldyhyde fixed lung samples were dehydrated, and
embedded in paraffin, and 5 μm sections were cut and collected on microscope
slides and H&E staining was performed (Shandon-Lipshaw) according to
manufacturer’s instructions. For CD73 immunostaining, HOPE-fixed sections
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were deparaffinized in isopropanol at 60°C and rehydrated in 70% acetone.
Rehydrated slides were quenched with 1% hydrogen peroxide and endogenous
avidin and biotin blocking was performed using a Biotin Blocking System (DAKO
Corp.). Slides were incubated with Mouse Anti-human CD73 Antibody (Hycult
Biotechnology, 1:50 dilution, overnight at 4°C). For A2BR immunostaining,
rehydrated slides were quenched with 1% hydrogen peroxide, antigen retrieval
performed (Dako Corp.), and endogenous avidin and biotin blocking was
performed using a Biotin Blocking System (DAKO Corp.). Slides were incubated
with Rabbit Anti-human A2BR Antibody (Chemicon, 1:500 dilution, 1 hour room
temperature). ABC Streptavidin reagents and individual appropriate secondary
antibodies were used to incubate the sections, and then sections were developed
with 3, 3'-diaminobenzidine (Sigma-Aldrich) and stained with methyl green.
Slides were coversliped with Vectashield (Vector Laboratories) mounting
medium.

Immunocolocalization
Paraformaldyhyde fixed lung samples were dehydrated, and embedded in
paraffin, and 5 μm sections were cut and collected on microscope slides. For
immunofluorescence on tissue sections, rehydrated slides were fixed in 1:1
acetone-methanol and treated with 1% NaBH4. Slides were blocked in 1% BSA,
and

incubated

overnight

at

4°C

with

the

primary

antibodies.

For

immunofluorescence on primary human macrophages, cells were cytospun and
fixed in 3.7% paraformaldehyde in PBS and permeabilized in cold Methanol.
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Slides were blocked with 1% rabbit serum and incubated overnight at 4°C with
the primary antibodies. Primary antibodies include: Mouse Anti-human CD73
Antibody (Hycult Biotechnology, 1:50 dilution), Rabbit Anti-human A2BR Antibody
(Chemicon, 1:500 dilution), Rat Anti-human MMR (CD206) Antibody (R&D
Systems, 1:50 dilution). Sections and cells were incubated with the following
secondary antibodies: Alexa Fluor 488 rabbit anti-mouse IgG, Alexa Fluor 488
goat anti-rabbit IgG, Alexa Fluor 568 goat anti-rat IgG (Intritrogen) then
coversliped with Vectashield with DAPI (Vector Laboratories).

In vitro Stimulation of Human Primary Alveolar Macrophages
Primary alveolar macrophages were obtained from BAL fluid of Severe
IPF and Stage 4 COPD patients. BAL fluid was spun and cell pellets were
resuspended

in

RPMI1640

containing

10%

FBS

and

10,000

U/ml

penicillin/streptomycin. Cells were portioned into aliquots of 2 X 105 cells/well,
allowed to adhere for 4 hours at 37◦C 5% CO2, and then rinsed twice with
RPMI1640 without FBS. Cells were either preincubated with 100nM CVT-6883
(selective A2BR antagonist) for 30 min followed by NECA or incubated with NECA
alone (in DMSO, 10µM NECA/well; Tocris Bioscience) for 12 h at 37◦C 5% CO2.
Tissue culture supernatants were collected and IL-8 and IL-6 levels were
quantitated using Human Quantikine ELISA kits (R&D Systems).
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Statistics
As appropriate, groups were compared by analysis of variance; follow-up
comparisons between groups were conducted using 2-tailed Student’s t test.
Associations between transcript levels of two genes were established by linear
regression. Correlation significances were analyzed using Pearson correlation
calculator software. Values are expressed as mean ± SEM. A P value of ≤0.05
was considered to be significant.
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CHAPTER 3
ENHANCED AIRWAY INFLAMMATION AND
REMODELING IN ADENOSINE DEAMINASEDEFICIENT MICE LACKING THE A2B ADENOSINE
RECEPTOR

INTRODUCTION

A2BR Antagonism in ADA-Deficient Mice
To investigate the contribution of A2BR signaling in the pulmonary
inflammation and injury observed in ADA-deficient mice, ADA-deficient mice
were treated with the selective A2BR antagonist CVT-6883. Following the
treatment, reduced influx of neutrophils and macrophages into the lungs of ADAdeficient mice was seen and this was associated with decreased expression
levels of cytokine and chemokine. Meanwhile, the A2BR antagonist treatment also
resulted in decreased alveolar airspace destruction and diminished expression of
matrix metalloprotease. Moreover, ADA-deficient mice treated with the antagonist
showed attenuated pulmonary fibrosis, which was accompanied by decreased
production of pro-inflammatory and pro-fibrotic mediators such as IL-6, TGF-β1
and osteopontin. These findings suggest that the activation of the A2BR mediates
many of the pathological phenotypes seen in the lungs of ADA-deficient mice.
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Treatment with the antagonist resulted in diminished pulmonary inflammation,
fibrosis, and airspace enlargement, suggesting that the A2BR plays a proinflammatory, tissue destructive role in this model (57).

Experimental Rationale and Goal
In addition to the findings in ADA deficient mice, substantial evidence has
suggested a tissue destructive role of the A2BR. Studies showed that
engagement of the A2BR promotes the differentiation of pulmonary fibroblasts
into myofibroblasts and hence increases the deposition of collagen and fibrosis
(30). Engagement of the A2BR can mediate the direct expression of proinflammatory cytokines such as IL-8, IL-4 and IL-13 from human HMC-1 mast
cells (53, 55). However, these findings are in contrast to recent studies in A2BR
knockout mice. The ablation of the A2BR causes low-grade inflammation and
enhanced leukocyte adhesion to the vasculature (58). In mouse models of
hypoxia and ventilator-induced pulmonary injury, treatment with an A2BRselective antagonist in wild type mice resulted in enhanced pulmonary edema,
inflammation, and attenuated gas exchange. Similar findings were observed in
mice with genetic deletion of the A2BR gene, where A2BR-/- mice showed
increased pulmonary damage following acute injuries. Moreover, A2BR agonist
treatment could attenuate the pulmonary damage and reverse injury (14, 15, 39).
These findings indicate that adenosine and A2BR signaling play a critical role in
the maintenance of pulmonary barrier function. In addition, loss of this Gscoupled receptor on mouse bone marrow-derived mast cells results in decreased
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levels of cAMP and enhanced mast cell activation (59). In order to further
investigate the role of the A2BR, we genetically removed the A2BR from ADAdeficient mice to further characterize the function of the A2BR in adenosinemediated pulmonary injury and tissue remodeling. Results indicate that the
genetic removal of A2BR from ADA-deficient mice leads to the exacerbation of
pulmonary disease, which suggests a critical role for this receptor in protecting
pulmonary disorders where elevated adenosine levels are involved.

RESULTS
Elevated A2BR Expression in the Lungs of ADA-Deficient Mice
In order to determine if there is enhanced A2BR signaling in ADA-deficient
mice, levels of A2BR transcripts in the lungs of ADA-deficient (ADA-/-) mice was
determined by semiquantitative RT-PCR. A2BR transcripts were detectable in the
lungs of ADA-containing (ADA+) and ADA-/- mice, which was significantly
elevated in the lungs of ADA-/- mice (Figure 3.1A). Quantitative RT-PCR was
used to confirm these findings. A mean 2.5-fold increase of A2BR transcripts in
whole-lung RNA extracts was observed in ADA-deficient mice (Figure 3.1B).
These findings demonstrate that A2BR transcripts are elevated in the lungs of
ADA-/- mice.
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Hayes
Young
Figure 3.1
The expression of A2BR in the lungs of ADA-/- mice. (A) Transcript levels for
the A2BR were measured in whole lung mRNA extracts from ADA-containing
(ADA+) and ADA-deficient (ADA-/-) mice on postnatal day 18, using
semiquantitative RT-PCR. Findings from 2 different pairs of littermates are
shown. RNA extracted from the colon of an ADA+ mouse was used as a
positive control, and β-actin was used as an RNA-positive control for each
sample. M, DNA size ladder. (B) Quantitative RT-PCR was used to determine
the levels of A2BR transcripts in day 18 whole-lung extracts from ADA+ and
ADA-/- mice. Data are presented as mean percentage of β-actin transcripts ±
SEM; n = 4 for each. *p≤0.05 compared to ADA+.
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ADA/A2BR Double Knockout Mice Exhibit Enhanced Pulmonary Pathology
and Die Precociously
ADA-/- mice were mated with A2BR-/- mice to generate ADA/A2BR double
knockout mice to assess the effect of genetically removing A2BR on the
pulmonary phenotypes seen in ADA-/- mice. ADA-/- mice develop progressive
pulmonary inflammation and die between postnatal day 18-21 (47). ADA/A2BR
double knockout mice did not survive past postnatal day 11-12 (data not shown).
These findings demonstrate that genetic removal of the A2BR from ADA-/- mice
leads to precocious lung injury and death. The death of animals at such a young
age made detailed assessment of pulmonary phenotypes difficult. In order to
circumvent this problem, ADA-/- mice and ADA/A2BR double knockout mice were
maintained on exogenous ADA enzyme therapy from birth and for the first 21
days of life and examined following the removal of ADA enzyme therapy. ADA-/mice treated in this manner exhibit signs of respiratory distress approximately 16
days after the cessation of ADA enzyme therapy. In contrast, ADA/A2BR double
knockout mice began to show signs of respiratory distress as early as day 11
after the cessation of enzyme therapy, and this labored breathing became
increasingly severe up to the death of the animals around postnatal day 16.
Therefore, detailed phenotype analysis was conducted 14 days after the
cessation of ADA enzyme therapy. At this stage, ADA-/- mice had diffuse
monocytic inflammation when compared to that seen wild type mice (Figure
3.2C). There was no evidence of inflammation in ADA+A2BR-/- mice (Figure 3.2B)
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Figure 3.2
Histopathology of the lungs. Lungs were collected on postnatal day 35 and
prepared routinely for sectioning and H&E staining. (A) Lung section from an
ADA+A2BR+/+ mouse. (B) Lung section from an ADA+A2BR-/- mouse. (C) Lung
section from an ADA-/-A2BR+/+ mouse. (D) Lung section from an ADA-/-A2BR-/mouse. Sections are representative of 6–8 different mice from each genotype.
Scale bars=100 μm.
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while enhanced pulmonary inflammation and increased congestion of the alveoli
were observed in ADA/A2BR double knockout mice (Figure 3.2D).

Enhanced Pulmonary Inflammation in ADA/A2BR Double Knockout Mice
To quantify the level of inflammation in ADA/A2BR double knockout mice,
bronchial alveolar lavage (BAL) was performed and cells recovered from BAL
Fluid were counted on a hemacytometer. There was a significant increase in the
number of inflammatory cells recovered from ADA/A2BR double knockout mice
compared to that seen in the lungs of ADA-/- mice containing the A2BR (Figure
3.3A). Differential staining of recovered airway cells demonstrated a significant
increase in neutrophils and lymphocytes as well as alveolar macrophages. Many
of these macrophages were activated and enlarged to form foam cells (Figure
3.3, B and C). To better visualize the increase in lung neutrophilia, lung sections
were immunostained using an antibody against mouse neutrophils. There were
robust increases in tissue neutrophils in the lung parenchyma of ADA/A2BR
double knockout mice compared to ADA-/- mice (Figure 3.3, D and E). Taken
together, these data suggest that enhanced pulmonary inflammation is seen in
the lungs of ADA-/- mice lacking the A2BR.

33

Figure 3.3
Pulmonary inflammation. (A) BAL fluid was collected on postnatal day 35 and
total cell numbers were determined. (B) BAL cells were cytospun and stained
with Diff-Quick, allowing for determination of cellular differentials. Data are mean
cell counts ± SEM. *p ≤ 0.05 versus ADA+ mice; #p ≤ 0.05 versus ADA-/-A2BR+/+
mice; n = 6 (ADA+), 8 (ADA-/-). (C) Cytospun BAL cells stained with Diff-Quick.
Scale bars=10 μm. (D) Lung section from an ADA-/-A2BR+/+ mouse and an ADA-/A2BR-/- mouse (E) were stained with an antibody against neutrophils to visualize
infiltrated tissue neutrophils (brown). Scale bars=100 μm.
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Inflammatory Cytokine and Chemokine Production Is Enhanced in
ADA/A2BR Double Knockout Mice
In order to better understand the mechanisms involved in the regulation of
inflammatory responses in ADA/A2BR double knockout mice, transcript levels of
cytokines and chemokines were monitored in whole-lung RNA extracts. TNF-α
transcript levels were elevated in the lungs of ADA-/- mice, and they were further
elevated in the absence of the A2BR (Figure 3.4A). IL-6 transcripts were elevated
in the lungs of ADA-/- mice. Surprisingly, they were significantly decreased with
the removal of the A2BR (Figure 3.4B). Levels of chemokines were also
examined, levels of monocyte chemotactic protein-1 (MCP-1) and CXCL-1 were
found to be significantly increased in the lungs of ADA-/- mice and levels of
CXCL-1 were further elevated after the genetic removal of the A2BR (Figure3.4, C
and D). These data indicate that removal of the A2BR results in exaggerated
transcription of TNF-α and CXCL-1 in the lungs of ADA-/- mice,whereas selective
removal of A2BR leads to decreased IL-6. Additionally, cytokine and chemokine
protein levels were determined in plasma and BAL fluid using the Milliplex mouse
cytoline/chemokine panel (Table 3.1). Plasma cytokine and chemokine protein
levels were measured to determine the status of systemic inflammation. CXCL-1
and MCP-1 protein levels were elevated in the plasma of ADA-/- mice, and levels
were significantly elevated after the genetic removal of the A2BR. Levels for IL-1α
and IL-1β were not elevated in ADA-/- mice containing the A2BR; however, they
were significantly increased in ADA/A2BR double knockout mice. Interestingly,
MIG protein levels were decreased in the plasma of ADA-/- mice and were further
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Figure 3.4
Production of proinflammatory cytokines. Transcript levels of various
proinflammatory cytokines were measured in whole-lung extracts from postnatal
day 35 mice using quantitative RT-PCR. Shown are levels of (A) TNF-α, (B) IL-6,
(C) CXCL1, (D) MCP-1. Results are presented as mean fold increase compared
to controls or mean pg transcript/μg RNA ± SEM. *p ≤ 0.05 versus ADA+ mice; #p
≤ 0.05 versus ADA-/-A2BR+/+ mice. n = 4 (ADA+), 8 (ADA-/-).
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Table 3.1 Cytokine and Chemokine Protein Levels in Plasma and BAL Fluid
Plasma (pg/ml)

BALF (pg/ml)

ADA+A2BR+/+

ADA+A2BR-/-

ADA-/-A2BR+/+

ADA-/-A2BR-/-

ADA+A2BR+/+

ADA+A2BR-/-

ADA-/-A2BR+/+

ADA-/-A2BR-/-

CXCL-1

111±10

155±18

493±121*

1086±191#

3±1

5±1

50±24*

116±29#

MCP-1

7±1

11±4

27±8*

190±98#

18±16

26±14

153±83*

245±85

LIF

ND

ND

ND

ND

0.3±0.2

0.1±0.1

9±4*

26±8#

RANTES

18±4

25±4

18±6

20±4

0.4±0.3

0.2±0.1

0.6±0.2

2±1#

MIG

143±21

123±8

41±14*

19±3

ND

ND

ND

ND

IL-1α

89±19

52±6

68±37

522±218#

4±1

5±2

2±1

3±2

IL-1β

17±4

26±4

33±7

81±29#

5±2

4±1

5±1

5±1

Levels of inflammatory mediators in plasma and BAL fluid. Plasma and BAL fluid were
collected from postnatal day 35 mice. Protein levels of inflammatory cytokines and
chemokines were determined by luminex assay. Data are presented as mean ± SEM.
*p ≤ 0.05 versus ADA+ mice; #p ≤ 0.05 versus ADA-/-A2BR+/+ mice. n = 4 (ADA+), 6
(ADA-/-). ND, not detected.

37

decreased in ADA/A2BR double knockout mice. BAL fluid protein levels were
used to examine cytokines and chemokines in these mice. Levels of CXCL-1 and
LIF-1 were elevated in the lungs of ADA-/- mice, and levels were significantly
elevated after the genetic removal of the A2BR. RANTES protein levels were not
changed in the BAL fluid of ADA-/- mice containing the A2BR; however, they were
significantly elevated in ADA-/- mice lacking the A2BR. MCP-1 protein levels were
not changed after the genetic removal of the A2BR though they were increased in
ADA-/- mice compared to wild type mice. These data suggest that the A2BR
differentially regulates the expression of cytokines and chemokines where
elevated adenosine level is involved.

Expression of Cell Adhesion Molecules in the Absence of the A2BR
It has been demonstrated that the removal of the A2BR is associated with
the activation of NF-κB pathways as indicated by down-regulation of the NF-κB
inhibitor IκB-α, and hence the up-regulation of adhesion molecules such as Eselectin, P-selectin, and ICAM-1 (58). Increased expression of cell adhesion
molecules is the potential underlying mechanism for the adhesion of leukocytes
to blood vessels and the migration to sites of infection in the tissue. Based on the
fact that more infiltrated neutrophils were found in the lung of ADA/A2BR double
knockout mice compared to that in ADA-/- mice, we examined the expression
levels of adhesion molecule as well as IκB-α. Whole lung extracts from postnatal
day 22 and day 35 mice were subjected to Western Blot analysis to determine
38

Figure 3.5
Western blot analysis of E-selectin, ICAM-1 and IκB-α in whole lung extracts.
Samples from postnatal day 22 (A) and postnatal day 35 (B) mice were subjected
to Western blotting with the indicated antibodies. Probing with anti-actin was used
as loading controls.
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the protein levels of E-Selectin, ICAM-1 and IκB-α. Day 22 was examined
because it is a stage when adenosine levels are not elevated in ADA-/- mice and
it is a stage that precedes the appearance of phenotypes. The expression of ESelectin, ICAM-1 and IκB-α were not altered in all genotypes compared to the
controls on day 22 (Figure 3.5A). However, on day 36 when the disease status is
established and adenosine levels are high, the expression of E-Selectin and
ICAM-1 were elevated in ADA-/- mice and ADA/A2BR double knockout mice,
though there was no apparent difference in the level of expression with or without
the A2BR (Figure 3.5B). In addition, the expression of IκB-α was not altered in all
genotypes (Figure 3.5, A and B). These data demonstrate that there is no
baseline activation of NF-κB and increased expression of cell adhesion
molecules in the lung in the absence of the A2BR. The increased expression of
these adhesion molecules lead to the inflammation seen in ADA-/- mice but
enhanced tissue neutrophilia in ADA/A2BR double knockout mice compared to
that in ADA-/- mice is likely not due to enhanced neutrophil adhesion.

Enhanced Vascular Permeability in ADA/A2BR Double Knockout Mice
Previous studies have shown a central role of the A2BR in the preservation
of endothelial barrier functions during hypoxia (14). We hypothesized that A2BR
deficiency would significantly influence vascular leakage in ADA-/- mice. To
assess this, BAL fluid was collected from postnatal day 35 mice and total protein
levels were determined. Total protein content was elevated in the lungs of ADA-/40

Figure 3.6
Vascular permeability analysis. (A) BAL fluid was collected from postnatal day 35
mice and total BALF protein levels were determined by Bradford assay. Data are
mean total protein content ± SEM. *p ≤ 0.05 versus ADA+ mice; #p ≤ 0.05 versus
ADA-/-A2BR+/+ mice. n = 6 (ADA+), 8 (ADA-/-). (B) Lungs from postnatal day 35
mice were collected and lung water content was determined by lung wet-dry
weight ratio. Data are mean ratio ± SEM. *p ≤ 0.05 versus ADA+ mice; #p ≤ 0.05
versus ADA-/-A2BR+/+ mice. n = 4 (ADA+), 6 (ADA-/-). Mice were administered
intraperitoneal Evan blue dye (0.2 mL of 0.5% in PBS) and sacrificed 4 hours
later and the hearts and lungs were harvested. (C) Representative images of
lungs. Evan blue dye concentrations were quantified in heart (D) and lung (E) as
described in "Methods". Data are mean dye content ± SEM. *p ≤ 0.05 versus
ADA+ mice; #p ≤ 0.05 versus ADA-/-A2BR+/+ mice. n = 4 (ADA+), 6 (ADA-/-).
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mice, and increases were markedly enhanced in the absence of the A2BR (Figure
3.6A). Lung water content was determined by measuring lung wet-dry weight
ratio. ADA deficiency was associated with a significant degree of lung water
increase. However, this increase was not affected by the genetic removal of the
A2BR (Figure 3.6B). However, comparative analysis of vascular permeability as
assessed by Evans blue dye extravasation revealed that vascular leakage was
significantly increased in lungs of ADA/A2BR double knockout mice compared to
that in ADA-/- mice (Figure 3.6, C and E). Basal permeability in ADA+ mice was
not altered with or without the A2BR (Figure 3.6, D and E). These findings
demonstrate that signaling through the A2BR is a critical control point for
pulmonary endothelial barrier function associated with elevated levels of
adenosine in ADA-/- mice.

Enhanced Mucous Cell Metaplasia in the Lungs of ADA/A2BR Doubleknockout Mice
One of the prominent features seen in the bronchial airways of ADA-/- mice
is mucous cell metaplasia. To determine what impact genetically removing the
A2BR had on mucous cell metaplasia, tissue sections were stained with PAS, and
mucous cell metaplasia was quantitated by morphometry. In the bronchial
airways, A2BR-/- mice showed increased numbers of PAS-positive cells (Figure
3.7, A, B, and E). As expected, in the bronchial airways of ADA-/- mice, a large
number of mucin-containing cells were observed (Figure 3.7, C and E).
Moreover, in the bronchial airways of ADA/A2BR double knockout mice, there was

42

Figure 3.7
Mucus metaplasia. On postnatal day 35, lungs were collected and prepared for
sectioning and PAS staining. (A), Lung section from an ADA+A2BR+/+ mouse.
(B), Lung section from an ADA+A2BR–/– mouse. (C), Lung section from an ADA–
/–
A2BR+/+ mouse. (D), Lung section from an ADA–/–A2BR–/– mouse. Sections are
representative of eight different mice from each genotype. Bars, 100 µm. (E),
Mucus index was determined, and data are presented as mean mucus index ±
SEM. *, p 0.05 vs ADA+ mice; #, p 0.05 vs ADA–/–A2BR+/+ mice. n = 4
(ADA+A2BR+/+ and ADA+A2BR–/–), n = 8 (ADA–/–A2BR+/+ and ADA–/–A2BR–/–).
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Figure 3.8
Mucin Gene Expression. Whole lung RNA extracts were analyzed using
quantitative RT-PCR assays for Muc5ac (A), Muc5b (B) and Clca3 (C). Results
are presented as mean fold increase compared to controls ± SEM. *p ≤ 0.05
versus ADA+ mice; #p ≤ 0.05 versus ADA-/-A2BR+/+ mice. n = 4 (ADA+), 8 (ADA-/-).
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increased PAS staining (Figure 3.7, D and E). These results demonstrate that
mucin accumulated in A2BR-/- mice at baseline and that mucus metaplasia is
enhanced in ADA/A2BR double knockout mice.
Major mucin gene transcripts levels were quantitated by Real-time PCR.
Interestingly, although mucus metaplasia was enhanced in ADA/A2BR double
knockout mice, there were decreases in levels of expression of the major mucins,
Muc5ac (Figure 3.8A), and Muc5b (Figure 3.8B), and the mucous metaplasia
marker calcium-activated chloride channel 3 (Clca3) (Figure 3.8C). This finding
suggests that the A2BR may play an important role in mucin secretion. Although
mucin gene expression is decreased in the double-knockout mice compared to
ADA-deficient mice, the defect in mucociliary clearance lacking the A2BR would
still result in enhanced mucus accumulation.

Enhanced Alveolar Destruction in the Lungs of ADA/A2BR Double Knockout
Mice
ADA-/- mice develop characteristics of emphysema

and features of

alveolar airspace enlargement (47). To determine whether A2BR was involved in
mediating airspace enlargement, alveolar destruction was analyzed in ADA-/mice and ADA/A2BR double knockout mice 14 days after the cessation of
exogenous ADA enzyme therapy. The size of alveolar airspaces in ADA-/- mice
showed a significant increase (Figure 3.9, C and E). The degree of airspace

45

Figure 3.9
Alveolar airspace enlargement. Lungs from postnatal day 35 mice were
infused with fixative under constant pressure (25 cm H2O) and processed for
H&E staining. (A) Lung section from an ADA+/A2BR+/+ mouse. (B) Lung section
from an ADA+A2BR-/- mouse. (C) Lung section from an ADA-/-A2BR+/+ mouse.
(D) Lung section from an ADA-/-A2BR-/- mouse. Images are representative of 68 animals from each genotype. Scale bars=100 μm. (E) Alveolar airspace size
was calculated using ImagePro analysis software; data are mean chord length
± SEM. *p ≤ 0.05 versus ADA+ mice; #p ≤ 0.05 versus ADA-/-A2BR+/+ mice. n =
4 (ADA+), 6 (ADA-/-).
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Figure 3.10
TUNEL Staining. (A) TUNEL-stained lung section from an ADA-/- mouse. (B)
TUNEL-stained lung section from an ADA-/-A2BR-/- mouse. Images are
representative of eight animals from each genotype. (C), TUNEL-positive cells
were counted, and data are presented as mean TUNEL scores ± SEM. *, p
0.05 vs ADA+ mice; #, p 0.05 vs ADA–/–A2BR+/+ mice. n = 4 (ADA+A2BR+/+ and
ADA+A2BR–/–), n = 8 (ADA–/–A2BR+/+ and ADA–/–A2BR–/–). Bars = 100 µm.
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Figure 3.11
Collagen production. (A) Whole lung α1-pro-collagen transcript levels were
measured from postnatal day 35 mice using quantitative RT-PCR, and data are
presented as mean fold increase compared with controls or mean pg
transcript/µg RNA ± SEM. (B), Soluble collagen protein levels in BAL fluid from
postnatal day 35 mice were quantified using the Sircol assay. Results are
presented as mean collagen levels ± SEM. *, p 0.05 vs ADA+ mice; #, p 0.05 vs
ADA–/–A2BR+/+ mice. n = 4 (ADA+A2BR+/+ and ADA+A2BR–/–), n = 8 (ADA–/–A2BR+/+
and ADA–/–A2BR–/–).
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enlargement was further increased in the lungs of ADA/A2BR double knockout
mice (Figure 3.9, D and E). Consistent with these findings, increased apoptosis
in the alveolar airspaces of ADA/A2BR double-knockout mice were observed
compared to ADA-/- mice (Figure 3.10). This finding demonstrates that there is
increased alveolar destruction in the lungs of ADA/A2BR double knockout mice.
Enhanced Pulmonary Fibrosis in ADA/A2BR Double Knockout Mice
Enhanced extracellular matrix deposition and collagen production are
prominant features noted in the lungs of ADA-/- mice. Examination of the
transcript levels of α-1 procollagen (Figure 3.11A) and soluble BAL collagen
levels (Figure 3.11B) revealed enhanced collagen production and signs of
enhanced pulmonary fibrosis in the lungs of ADA/A2BR double-knockout mice.
Enhanced Tracheal Vascularity in ADA/A2BR Double Knockout Mice
ADA-/- mice have increased tracheal vascularity in association with elevated
adenosine levels (65). To determine whether A2BR plays a role in regulating
tracheal vascularity, CD31 whole mount immunohistochemistry was performed
on tracheas (Figure 3.12). Consistent with the previous finding, results suggest
that there are increased numbers of vessel in ADA-/- mice compared to wide type
mice. Interestingly, ADA/A2BR double knockout mice exhibited further increased
tracheal vascularity compared with ADA-/- mice possessing the A2BR (Figure
3.12). These results indicate that the genetic removal of the A2BR leads to
enhanced tracheal angiogenesis in ADA-/- mice.
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Amir Mohsenin
Figure 3.12
Tracheal vascularity and angiogenesis. (A) Tracheas were removed from
postnatal day 35 mice and angiogenesis was analyzed by whole mount CD31
immunostaining for the visualization of vessels. Results are representative of 4
mice from each genotype. Scale bars=100 μm. (B) Tracheal vascularity was
determined in the samples shown in A by counting the number of vessels
intersecting a line down the length of the cartilage ring. At least 12 cartilage rings
were analyzed per sample. Data are represented as mean vessels (in
millimeters) ± SE; n = 4. *p ≤ 0.05 versus ADA+ mice; #p ≤ 0.05 versus ADA-/A2BR+/+ mice.
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Adenosine Levels in ADA/A2BR Double Knockout Mice
To determine if elevated adenosine levels in ADA/A2BR double knockout
mice could contribute to the enhanced pulmonary pathology, adenosine levels in
BAL fluid were quantitated using HPLC. Results suggest that there are increased
adenosine levels in ADA-/- mice compared to wide type mice. Interestingly,
adenosine levels were not further elevated in ADA/A2BR double knockout mice
compared with ADA-/- mice possessing the A2BR (Figure 3.13).

DISCUSSION

Adenosine can have both tissue-protective and tissue-destructive
functions depending on endogenous adenosine concentrations generated
following injury, the nature and duration of injury, and the expression profile of
each adenosine receptor on specific cell types (22, 66). Adenosine’s tissuedestructive role is supported by the ADA-deficient mouse model where elevated
adenosine levels lead to features of chronic lung disease including inflammation,
mucin overproduction, alveolar airway enlargement, fibrosis and angiogenesis
(47, 65). The A2BR is widely expressed in tissues and has been indicated to play
an important role in inflammation and tissue remodeling. In the current study,
A2BR was genetically removed from ADA-deficient mice to generate double
knockout mice to examine the contribution of the A2BR to the pulmonary
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Figure 3.13
Adenosine levels in BAL fluid. BAL fluid was collected on postnatal day 35 and
adenosine levels were measured using reversed phase HPLC. Data are
presented as mean nmol adenosine ± SEM. n = 3 for each group. * p ≤ 0.05
versus ADA+ mice.
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phenotype seen in ADA-deficient mice. Findings demonstrate that the genetic
removal of the A2BR from ADA-deficient mice leads to precocious lung injury and
death. The precocious pulmonary damage and death of these mice was
associated with increased lung inflammation, vascular permeability, alveolar
destruction and tracheal angiogenesis. These results demonstrate that the A2BR
plays an important role in protecting pulmonary inflammation and damage seen
in ADA-deficient mice.

One of the major observations in this study was that ADA/A2BR double
knockout mice exhibited enhanced pulmonary inflammation compared to ADAdeficient mice possessing the A2BR. There were increases in lymphocytes and
particularly neutrophils in the BAL fluid of ADA-deficient mice lacking the A2BR.
Consistent with this, immunostaining showed that there were more neutrophils in
the lungs of ADA/A2BR double knockout mice compared to ADA-deficient mice,
suggesting that A2BR signaling may be protective in regulating pulmonary
neutrophilia. These findings differ somewhat from our recent observations that
blockade of the A2BR in ADA-deficient mice using an A2BR antagonist results in
diminished pulmonary inflammation (57). The A2BR has been shown to exhibit
both pro- and anti-inflammatory functions. The first in vivo evidence showing
A2BR’s anti-inflammatory roles comes from a study where the genetic ablation of
the A2BR was associated with low-grade inflammation that was associated with
the augmentation of pro-infammatory cytokines, such as TNF-α, and a
consequent downregulation of Iκb-α, the inhibitor of NF-κB signaling pathway. In
this study, the activation of NF-κB was proposed to lead to the expression of pro53

inflammatory cytokines, chemokines and cell adhesion molecules (58). We
therefore examined whether activation of these pathways might account for the
increased neutrophil counts seen in the lungs of ADA/A2BR double knockout
mice. Interestingly, expression levels of cell adhesion molecules such as ICAM-1
and E-selectin were not altered in the lungs of ADA-deficient mice lacking the
A2BR, nor was expression of Iκb-α affected. Thus, activation of NF-κB signaling
pathways and altered adehesion molecule expression do not appear to be
responsible for enhanced pulmonary inflammation in ADA/A2BR double knockout
mice.

However, our experiments did reveal an increase in pulmonary vascular
permeability in the lungs of ADA/A2BR double knockout mice, which may account
for the increased neutrophil infiltration into the lung. This is consistent with the
observations that pharmacologic blockade and genetic removal of the A2BR is
central to hypoxia-associated vascular leak (14). Activation of the A2BR is
associated with increases in intracellular cAMP concentration following activation
of PKA. PKA-induced phosphorylation of vasodilator-stimulated phosphoprotein
(VASP) may result in changes in junctional protein geometry and distribution, and
hence regulating the characteristics of the junctional complex, leading to barrier
function increases (3, 67, 68). Hypoxia exposure and ADA deficiency both result
in a prolonged action of extracellular adenosine and enhanced adenosine
signaling. Adenosine plays a protective role in controlling vascular leakage that
mice deficient in enzymes involved in extracellular adenosine generation showed
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profound increases in vascular leakage (3, 69). Therefore, the genetic removal of
the A2BR from ADA-deficient mice may lead to enhanced vascular permeability
and subsequent neutrophil accumulation in the tissue.

Inflammatory cell accumulation in the lung occurs following proinflammatory stimuli that result in the recruitment of cells into tissue from the
circulatory system. Thus, increased expression levels of inflammatory cytokines
and chemokines could also contribute to neutrophil infiltration into the lungs.
Transcript levels of TNF-α and CXCL-1 were elevated in the lungs of ADAdeficient mice, and levels were markedly increased in the absence of the A2BR.
Interestingly, IL-6 levels were decreased with the removal of the A2BR,
suggesting the A2BR regulates the production of IL-6 in this model. Consistent
with this, engagement of the A2BR increases IL-6 release from bronchial smooth
muscle cells (70), human lung fibroblasts (30), and airway epithelia (71); while
adenosine inhibits TNF-α release from mouse peritoneal macrophages and
human monocytes via the A2BR (72, 73). Additionally, cytokine and chemokine
protein levels were determined from BAL fluid and plasma to monitor the
inflammatory status in lung and systemically. As expected, levels of CXCL-1, LIF1 and RANTES were elevated in BAL fluid from ADA/A2BR double knockout mice
compared to that in ADA-deficient mice. Although expression levels of certain
cytokines and chemokines did increase after the genetic removal of the A2BR
from ADA-deficient mice, we did not see increased percentage of neutrophils in
peripheral white blood cell counts (data not shown). As a result, increases in lung
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neutrophil mumbers appeared to depend largely on enhanced vascular
permeability following the genetic removal of the A2BR.
An interesting finding in this study is that mucus metaplasia was enhanced
in ADA/A2BR double-knockout mice, consistent with the other enhanced
pulmonary histopathology. However, there was a decrease in degree of
expression of the major mucin genes and mucous metaplasia marker Clca3.
Although we cannot rule out the roles of other mucin genes that possibly take
part in mucus accumulation, this finding suggests that the A2BR may play an
important role in mucociliary clearance. Previous studies have shown that the
A2BR is an important regulator of cystic fibrosis transmembrane conductance
regulator (CFTR) functions and lacking this receptor may lead to dehydration of
airway surface liquid volume and mucus stasis (74). As a result, even thought
there was decreased mucin gene expression in the absence of A2BR signaling,
the defect in mucus clearance would still lead to mucus accumulation in the
airways. Further studies are needed to clarify the role of the A2BR in mucin gene
expression as well as mucociliary clearance.
Another prominent feature of ADA/A2BR double knockout mice was
enhanced tissue remodeling, including destruction of alveolar airspaces, a
response reminiscent of emphysema, and trachea angiogenesis (47, 61, 62).
The degree of the enlargement of airspace was significantly increased in the
lungs of ADA-deficient mice lacking the A2BR. It is possible that this pulmonary
phenotype noted in ADA/A2BR knockout mice is attributed to the increases in
pulmonary neutrophils seen. For example, neutrophils produce degradative
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enzymes such as matrix metalloproteinase-9 and neutrophil elastase, which can
contribute to alveolar airway enlargement and could account for the enhanced
airspace enlargement seen in ADA/A2BR double knockout mice exhibiting
increases in airway neutrophils. ADA-deficient mice have increased tracheal
angiogenesis in association with increased CXCL-1 level (65). Similarly, the
current study showed that enhanced tracheal vascularity is associated with
increased CXCL-1 expression seen in the lungs of ADA/A2BR double knockout
mice. These findings demonstreate that CXCL-1 level in the lung may directly
regulates pathological angiogenesis and may serve as an important therapeutic
target.

Overall,

ADA/A2BR

double

knockout

mice

have

enhanced

lung

inflammation and tissue destruction when compared to ADA-deficient mice that
express the A2BR. These observations contradict those seen in this same model
following A2BR antagonism (57). In the A2BR antagonism study, ADA-deficient
mice were kept on Peg-ADA enzyme therapy till Day 21. Three days after the
removal of ADA enzyme therapy, the A2BR antagonist CVT-6883 was given
intraperitoneally. CVT-6883-treated ADA-deficient mice exhibited diminished
pulmonary inflammation, fibrosis, and alveolar airspace destruction, suggesting
the pro-inflammatory functions of the A2BR. Clearly, discrepancies exist while
characterizing the anti- or pro-inflammatory functions of the A2BR. In addition to
the finding from A2BR antagonism in ADA-deficient mice show A2BR’s tissuedestructive roles, engagement of the A2BR promotes the differentiation of
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pulmonary fibroblasts into myofibroblasts and hence increases the deposition of
collagen and fibrosis (30). A2BR activation also mediates the direct expression of
pro-inflammatory cytokines such as IL-8, IL-4 and IL-13 from human HMC-1 cells
(52, 53, 56). Stimulation of A2BRs up-regulates IL-6 production from mouse
macrophages (75), IL-13 and VEGF secretion from mouse bone marrow mast
cells (56). Inconsistent with these findings, A2BR plays an anti-inflammatory role
that tissue damage and injury could be amplified in the absence of A2BR
signaling. A2BRs are required for airway surface liquid (ASL) volume homeostasis
in human airways and therapies directed at inhibiting the A2BR may lead to
depleted ASL volume and mucus stasis (74). The ablation of the A2BR causes
low-grade inflammation, augmentation of pro-infammatory cytokines, such as
TNF-α, and a consequent activation of NF-κB signaling pathway (58). Loss of this
Gs-coupled receptor on mouse bone marrow-derived mast cells results in
decreased levels of cAMP and enhances mast cell activation (59).
The functions of A2BR signaling are also controversial in other organs. The
reno-vascular

A2BR

protects

the

kidney

from

ischemia

that

ischemic

preconditioning (IP) protection from ischemia was abolished in A2BR-/- mice while
treatment with the selective A2BR agonist dramatically improved renal function
and histology following ischemia injury (76). Blockade or deletion of the A2BR in a
mouse model of colitis showed reduced clinical symptoms, histological scores,
IL-6 and KC levels in the supernatants of colonic organ cultures (77, 78).
Interestingly, although colonic inflammation was attenuated in A2BR-/- mice
compared with their wild type counterparts, A2BR-/- mice actually showed

58

increased susceptibility to systemic Salmonella infection (77). It seems that in
most cases pharmacological blockage of the A2BR by antagonists is beneficial
while gene deletion of the A2BR generally enhances the phenotypes seen in
multiple organs and systemically after injury. The discrepancies between the
pharmacological block and gene knockout studies may be related to the nature of
injury, the specific organ environment, the levels and duration of adenosine
elevation, and the timing of A2BR antagonism. The A2BR may have a bi-phasic
effect on inflammation that the A2BR antagonist could be beneficial only when it is
given after the disease status is established, while the A2BR plays an important
protective role before the chronic stage of the disease. Moreover, the
discrepancy between these two studies could be due to the fact that the
antagonist may only have a partial affect in blocking the receptor activity while
genetic knockout completely abolishes the receptor signaling. Additionally, it has
been shown in the literature that the A2BR could be recruited to the plasma
membrance to form receptor dimers or a complex with other proteins, such as
ezrin, and compartmentalize E3KARP (79). For this reason, Ryzhov et al. argued
that mast cell activation and the increase in basal and LPS-stimulated TNF-α
release observed in A2BR-/- mice is not directly related to adenosine signaling
through the A2BR, but it may represent a loss of other unidentified functions of
this protein or reflect a developmental adaptation to the A2BR gene ablation (75).

In conclusion, the results of the present study demonstrated that the
genetic removal of the A2BR from ADA-deficient mice enhanced pulmonary
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inflammation and injury induced by increased adenosine levels. These findings
are inconsistent with the previous pharmacological study and the hypothesis that
A2BR signaling contributes to the pro-inflammatory and tissue-destructive
activities present in chronic lung diseases. The A2BR may have a bi-phasic effect
on inflammation that the A2BR antagonist may be beneficial only when it is given
after the disease status is established. Thus, cautions must be taken when
designing A2BR antagonist treatment strategies in human chronic lung disease.
The results of the present study demonstrated that the genetic removal of the
A2BR from ADA-deficient mice resulted in enhanced pulmonary inflammation and
injury induced by increased adenosine levels. The underlying mechanism for
enhanced tissue damage is thought to be excessive neutrophil infiltration caused
by loss of pulmonary vascular barrier function. These findings suggest that during
the acute stage of lung injury, A2BR plays a homeostatic and protective role such
as barrier function, but it plays a detrimental role during the chronic stage of
diseases such as pulmonary fibrosis. Moreover, inhibition of the A2BR may result
in collapsed airway surface liquid and mucus stasis that could potentially
accentuate disease status. Further studies are needed to understand the
complicated role of the A2BR, which will be critical for developing A2BR-based
therapies for the treatment of various diseases. In the next chapter, specific
experiments were designed to determine the potential mechanisms of the
destructive and protective components of A2BR signaling.
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CHAPTER 4
THE ROLE OF THE A2BR IN ACUTE AND CHRONIC
STAGES OF BLEOMYCIN-INDUCED LUNG
INJURY

In the previous chapter, I demonstrated that the genetic removal of the
A2BR from ADA-deficient mice results in enhanced pulmonary inflammation,
fibrosis and alveolar airspace enlargement. Enhanced pulmonary vascular
permeability due to the lack of the A2BR may be responsible for the increased
damage in the lung. This finding, together with the previous findings that A2BR
signaling promotes the expression of pro-inflammatory and pro-fibrotic mediators
(32, 53, 57), suggests that A2BR plays a protective role during the acute phase of
lung injury and promotes destructive features during chronic stages of the
disease. Studies described in this chapter focus on understanding the distinctive
roles of the A2BR at different stages of lung injury in another model of pulmonary
injury: the model of bleomycin-induced pulmonary injury.

INTRODUCTION
Bleomycin induced pulmonary fibrosis
Pulmonary fibrosis is characterized by extracellular matrix deposition,
aberrant fibroblast proliferation, and inflammation, which are distinctive features
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of interstitial lung diseases. These tissue remodeling processes result in
distortion of lung architecture and compromised pulmonary function (10).
Bleomycin is a glycopeptide antibiotic produced by the bacterium Streptomyces
verticillus and is a widely used anti-cancer agent. It functions by catalytically
generating double strand DNA breaks and results in apoptosis of affected cells
(80). The expression of bleomycin hydrolase, the enzyme that degrades
bleomycin, is particularly low in the lung and skin (81). As a result, the most
serious side effect of bleomycin is pulmonary fibrosis and impaired lung function
(82). About 1% of patients suffer from irreversible pulmonary fibrosis following
bleomycin exposure (83).
This side effect has been used to investigate the mechanisms of fibrosis.
Bleomycin results in similar lung parenchyma injury and interstitial fibrosis in
mice as is seen in humans (84). Lungs that have been exposed to bleomycin
show evidence of injury and inflammation, which involves an infiltration of
granulocytes, lymphocytes and monocytes (85). Ultimately, increased deposition
of extracellular matrix such as collagen and fibronectin in the alveolar wall
compromise pulmonary function (86, 87). Pulmonary injury in mice induced by
bleomycin delivered intratracheally or intraperitoneally are two well-established
animal models of lung fibrosis (88, 89); however, the route of delivery results in
different degrees of acute injury.
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IT versus IP bleomycin treatment
In the standard intratracheal (IT) bleomycin induced pulmonary injury
model, 10-week old female mice are exposed to a single dose of 2.5 U/kg
bleomycin IT. Mice develop significant pulmonary fibrosis at 21 days after
challenge. However, since bleomycin is instilled directly into the respiratory tract,
the acute damage caused by bleomycin results in extensive apoptosis of airway
epithelial cells, followed by an acute phase of pulmonary injury resulting in a
large amount of infiltrating granulocytes around Day 7 after the challenge. Most
granulocytes are resolved by Day 21 and macrophages and lymphocytes remain
in the airways. At this stage, mice develop severe fibrosis due to a failed wound
healing response. In contrast, in the intraperitoneal (IP) bleomycin model, 6-week
old male mice are treated with a higher dose of bleomycin IP twice a week for
four weeks. Since drug is delivered systemically into the peritoneal cavity and the
lung is not directly exposed to bleomycin directly, there is not excessive acute
injury or inflammation in the lung. However, when mice are sacrificed a week
after the last treatment on day 33, they do develop a significant amount of
pulmonary fibrosis.
Thus, IT bleomycin is a model of acute injury, followed by fibrosis, and IP
bleomycin is a model of mild injury and progressive pulmonary fibrosis.

Experimental Rational and Goals
In the previous studies, when ADA-deficient mice were treated with the
A2BR antagonist 3 days after the cessation of Peg-ADA treatment, they showed
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less pulmonary inflammation, fibrosis, and alveolar airspace enlargement
compared to ADA-deficient mice, suggesting pro-inflammatory and pro-fibrotic
functions of the A2BR. However, the genetic removal of the A2BR from ADAdeficient mice resulted in significantly enhanced pulmonary inflammation, fibrosis
and alveolar airspace enlargement, in which enhanced pulmonary vascular
permeability due to the lack of A2BR likely played an important role. As a result,
these studies provide the proof of concept that the A2BR is fundamental in
maintaining vascular barrier function during the acute phase of pulmonary injury,
while it is tissue-destructive during the chronic phase.
In order to further address this concept in another model of pulmonary
injury, we took the genetic approach to investigate the role of A2BR in the model
of bleomycin-induced pulmonary injury. We utilized the two different drug delivery
methods described above to determine the functions of the A2BR at different
stages of lung injury. We hypothesized that in the IP bleomycin model, since no
acute damage and inflammation are involved, A2BR-/- mice will show significantly
less pulmonary fibrosis compared to wild type mice; however, in the IT bleomycin
model, enhanced acute injury and inflammation will be observed in A2BR-/- mice
due to their compromised vascular barrier function. This may counteract the profibrotic functions of the A2BR and there will not be a significant difference when
assessing fibrosis at Day 21 endpoint in the IT model.
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RESULTS
Fibrosis in the IT bleomycin model
To determine the role of the A2BR in IT bleomycin-induced pulmonary
injury, wild type and A2BR-/- mice were exposed to a single dose of 2.5 U/kg
bleomycin IT and fibrosis was assessed 21 days after bleomycin exposure. Mice
exposed to saline were used as controls and they showed no sign of fibrosis on
Day 21 (Figure 4.1, A and C). Mice exposed to bleomycin exhibited significant
pulmonary fibrosis and extracellular matrix deposition; however, there did not
appear to be a difference in pulmonary histopathology when comparing wild type
mice (Figure 4.1B) to A2BR-/- mice (Figure 4.1D) exposed to bleomycin. To
assess the degree of fibrosis in these mice, the Sircol assay was used to
measure soluble collagen in BAL fluid, and Ashcroft scores were determined on
lung sections. Analysis showed that bleomycin exposure resulted in the same or
slightly decreased degree of fibrosis in A2BR-/- compared to wild type mice (Figure
4.1, E and F). These results suggested that, surprisingly, the genetic removal of
the A2BR did not lead to diminished nor enhanced development of pulmonary
fibrosis in the IT model.

Fibrosis in the IP bleomycin model
To investigate whether the route of bleomycin exposure affects the role of
the A2BR in bleomycin-induced injury, mice were treated with 8 doses of
bleomycin IP twice a week for 4 weeks. Fibrosis was assessed a week after the
last bleomycin exposure. Mice exposed to PBS were used as controls and
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Figure 4.1
Histopathology of the lungs. Lungs were collected 21 days after bleomycin exposure and
prepared routinely for sectioning and H&E staining. (A) Lung section from an A2BR+/+
mouse treated with saline. (B) Lung section from an A2BR+/+ mouse treated with
bleomycin. (C) Lung section from an A2BR-/- mouse treated with saline. (D) Lung section
from an A2BR-/- mouse treated with bleomycin. Sections are representative of 6-8
different mice from each genotype. Scale bars = 100 μm. (D) Ashcroft scoring was
conducted to determine the extent of fibrosis. (E) Soluble collagen protein levels in BAL
fluid were quantified using the Sircol assay. Results are presented as mean collagen
levels ± SEM. *, p 0.05 vs ADA+ mice treated with saline; #, p 0.05 vs A2BR+/+ mice
treated with bleomycin. n = 6 (saline treated), n = 8 (bleomycin treated).
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Figure 4.2
Histopathology of the lungs. Lungs were collected 33 days after the first bleomycin
exposure and prepared routinely for sectioning and H&E staining. (A) Lung
section from an A2BR+/+ mouse treated with PBS. (B) Lung section from an A2BR+/+
mouse treated with bleomycin. (C) Lung section from an A2BR-/- mouse treated
with PBS. (D) Lung section from an A2BR-/- mouse treated with bleomycin.
Sections are representative of 6-8 different mice from each genotype. Scale bars
= 100 μm. (D) Ashcroft scoring was conducted to determine the extent of fibrosis.
(E) Soluble collagen protein levels in BAL fluid were quantified using the Sircol
assay. Results are presented as mean collagen levels ± SEM. *, p 0.05 vs ADA+
mice treated with PBS; #, p 0.05 vs A2BR+/+ mice treated with bleomycin. n = 6
(saline treated), n = 8 (bleomycin treated).
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showed no signs of fibrosis (Figure 4.2, A and C). In contrast, wild type mice
exposed to bleomycin exhibited significant pulmonary fibrosis and extracellular
matrix deposition (Figure 4.2B). Interestingly, A2BR-/- mice exposed to bleomycin
had a diminished degree of fibrotic histopathology compared to wild type mice
(Figure 4.2D). To quantitate the degree of fibrosis in these mice, Ashcroft Scoring
was conducted and revealed that A2BR-/- had diminished fibrosis compared to
wild type mice (Figure 4.2E). The Sircol assay confirmed that levels of soluble
collagen in BAL fluid are significantly lower in A2BR-/- mice compared to that in
wild type mice (Figure 4.2F). These results suggested that the genetic removal of
the A2BR resulted in diminished pulmonary fibrosis in the IP model of bleomycininduced pulmonary injury.

Inflammation in the IT and IP bleomycin models
To examine the effects of the A2BR on pulmonary inflammation following
bleomycin-induced injury, the numbers of inflammatory cells recovered from BAL
fluid were quantitated at both the acute and chronic phase to determine the
status of pulmonary inflammation at early and late stages of the disease.
In the IT bleomycin model, direct damage to the lung results in an acute
inflammation. Indeed, our findings suggest that the total inflammatory cell
numbers recovered from BAL fluid was significantly increased 7 days after
bleomycin exposure. Interestingly, the number of total inflammatory cells was
significantly higher in A2BR-/- compared to wild type mice (Figure 4.3A, left panel).
Cell differentials suggested that increased numbers of macrophages and
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neutrophils were responsible for the total cell number increase. In animals
treated with bleomycin, the most significant difference between A2BR-/- mice and
wild type mice was that there were more infiltrated neutrophils in A2BR-/- mice
(Figure 4.3A, middle and right panels). At the chronic phase of the IT bleomycin
model, we still observed an increase in total cell number in mice treated with
bleomycin on Day 21. However, there was no difference in the number of total
cells between wild type and A2BR-/- mice (Figure 4.3B, left panel). Moreover, the
numbers of macrophages, lymphocytes and neutrophils were not altered in A2BR/-

mice compared to wild type animals (Figure 4.3B, middle and right panels). This

is consistent with our observation that there was no difference in fibrosis between
wild type and A2BR-/- mice. These findings suggest that IT bleomycin treatment in
A2BR-/- mice is associated with enhanced acute pulmonary inflammation and
neutrophil infiltration compared to wild type mice, whereas lacking the A2BR at the
chronic phase has no effect on pulmonary inflammation.
Examination of pulmonary inflammation in the IP bleomycin model was
also determined by counting the number of inflammatory cells recovered from
BAL fluid. At 10 days after the initiation of IP bleomycin treatments, the number
of total inflammatory cells was significantly increased. However, there was no
difference in the number of total cells between wild type and A2BR-/- mice (Figure
4.3C, left panel). Cell differentials suggested that most cells recovered were
macrophages. Importantly, there was no increased neutrophil infiltration in this
model. Moreover, there was no difference in the numbers of each cell types
between wild type and A2BR-/- mice (Figure 4.3C, middle and right panels). At the
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chronic phase of the IP bleomycin model, an increase in total cell number on Day
33 was also observed in mice treated with bleomycin. However, there was no
difference in the numbers of total cells and macrophages between wild type and
A2BR-/- mice (Figure 4.3D, left and middle panels). Interestingly, the numbers of
lymphocytes and neutrophils were significantly decreased in A2BR-/- mice
compared to wild type mice (Figure 4.3D, right panel). These findings suggest
that the IP bleomycin treatment was not associated with an acute inflammation
and neutrophil infiltration at the acute phase; even though decreased pulmonary
fibrosis was observed in A2BR-/- mice compared to wild type mice following
bleomycin exposure, lacking the A2BR at the chronic phase had only mild effect
on pulmonary inflammation.

Vascular permeability in the IT and IP bleomycin models
Acute lung injury is commonly associated with the loss of pulmonary
vascular barrier function, which can contribute to enhanced neutrophil infiltration
into the lung. Previous studies have shown that the A2BR plays a protective role
in the maintenance of pulmonary barrier function in various models of acute lung
injury (14, 39). Findings in chapter 4 of this dissertation suggest that the
enhanced loss of vascular barrier function in ADA/A2BR double knockout mice
resulted in enhanced pulmonary inflammation. Here I show that the IT bleomycin
model where an acute damage is involved, there is an increase in the number of
infiltrated inflammatory cells, specifically neutrophils, in A2BR-/- mice compared to
wild type mice at the acute phase of the injury. To determine if the loss of
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Figure 4.3
Pulmonary inflammation in the IT and IP bleomycin models. (A) BAL fluid was
collected 7 days after IT bleomycin exposure. (B) BAL fluid was collected 21 days
after IT bleomycin exposure. (C) BAL fluid was collected 10 days after IP bleomycin
exposure. (D) BAL fluid was collected 33 days after IP bleomycin exposure. Total cell
numbers were determined. Then BAL cells were cytospun and stained with DiffQuick, allowing for determination of cellular differentials. Data are mean cell counts ±
SEM. *p ≤ 0.05 versus mice treated with saline or PBS; #p ≤ 0.05 versus A2BR+/+ mice
treated with bleomycin; n = 8.
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Figure 4.4
Vascular permeability in the IT and IP bleomycin models. (A) 7 days after IT
bleomycin exposure or 10 days after the first IP bleomycin exposure, mice
were administered intraperitoneal Evan blue dye (0.2 mL of 0.5% in PBS) and
sacrificed 4 hours later. Lungs were harvested and Evan blue dye
concentrations were quantified as described in "Methods". (B) Representative
images of lungs. Data are mean dye amount ± SEM. *p ≤ 0.05 versus mice
treated with saline or PBS; #p ≤ 0.05 versus A2BR+/+ mice treated with
bleomycin; n = 6.
72

vascular barrier occurs in A2BR-/- mice, Evans blue dye extravasations were
quantitated four hours after injecting the dye intraperitoneally. Results revealed
that there was enhanced vascular leakage in A2BR-/- mice compared to that in
wild type mice after bleomycin induced injury (Figure 4.4, A and B). In contrast,
there was only mild damage at the acute phase of the IP bleomycin model.
Evans blue dye extravasations revealed that although vascular permeability was
enhanced following bleomycin exposure, there was no further loss of vascular
barrier function in mice lacking the A2BR (Figure 4.4, A and B).
These findings suggest that IT bleomycin exposure results in an acute
damage, making vasculature the fundamental barrier in preventing neutrophil
infiltration and injury to the lung. Thus, there is enhanced loss of vascular barrier
function and pulmonary neutrophilia in A2BR-/- mice at the acute stage of the
disease. In contrast, IP bleomycin model does not involve an acute damage and
there is only mild vascular damage in mice exposed to bleomycin and no further
loss of barrier function in A2BR-/- mice at the acute stage of the disease.

DISCUSSION
In the previous chapter, we observed that the genetic removal of the A2BR
results in loss of vascular barrier function in ADA-deficient mice. This may
contribute to the enhanced pulmonary injury at the acute stage of disease in
ADA/A2BR double knockout mice, leading to the precocious death of these
animals compared to ADA-deficient mice. However, in the same model, A2BR
antagonism resulted in diminished pulmonary inflammation and fibrosis,
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suggesting a tissue-destructive role of this receptor at chronic stage of the
disease. The discrepancy between these two studies could be due to the fact
that the A2BR antagonist was given after the disease status has been
established, while the genetic knockout totally abolished the receptor activity
from birth of the animals. Therefore, in ADA-deficient model, the A2BR may have
a bi-phasic effect on disease progression that it plays an important role in
maintaining vascular barrier function during acute injury and serves a proinflammatory and pro-fibrotic role during the chronic phase of the disease. In
order to further address this concept, I chose bleomycin-induced pulmonary
injury as the model to investigate the distinctive roles of the A2BR at different
stages of the disease.
The IT bleomycin model involves a single dose of bleomycin exposure
directly into the lung. The local exposure of the toxic drug results in a severe
apoptosis of epithelial cells and damage to the lung after it is delivered. In
addition to the result that mice develop extensive pulmonary fibrosis in the
interstitial areas of the lung, an acute inflammation characterized by neutrophil
infiltration is involved before the fibrotic changes. The instant damage caused by
bleomycin

makes

vasculature

maintanance

fundamentally

important

in

preventing the infiltration of inflammatory cells. When A2BR-/- mice were exposed
to bleomycin intratracheally, loss of vascular barrier function at the early stage of
the disease (Day 7) contributed significantly to the enhancement of pulmonary
inflammation. Furthermore, this enhanced inflammation counteracted the pro-
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fibrotic role of the A2BR and there was no difference in appearance of the lungs of
wild type and A2BR-/- mice after the development of fibrosis.
The generation of adenosine and subsequent A2BR signaling play tissueprotective roles during acute lung injuries (90). Previous studies have supported
the protective roles of adenosine and A2BR signaling. For example, the levels of
CD39 and CD73, the enzymes to generate adenosine, are elevated in the lungs
following LPS exposure (37). Moreover, the accumulation of neutrophils following
LPS stimulation is enhanced in mice deficient in CD39 or CD73. Similar findings
have been demonstrated in mouse models of hypoxia-induced and ventilatorinduced lung injuries. The levels of CD39 and CD73, and the expression of the
A2BR are increased during ventilator-induced and hypoxia-induced lung injuries
(3, 91). In addition, the A2BR’s protective roles were revealed by pharmacological
and genetic approaches. Enhanced pulmonary inflammation, edema, and
attenuated gas exchange were seen in mice treatment with an A2BR antagonist
and mice with the A2BR gene deletion (14, 92). In contrast, treatment with an
A2BR agonist attenuated the injuries and protected the lungs from drying out (39).
The A2BR’s protective role was also demonstrated in other organs. A2BR
blockage or gene deletion resulted in increased weight loss, colonic shortening,
and disease activity indices in a mouse colitis model, implicating a protective role
of the A2BR on intestinal epithelial cells (93). Furthermore, the A2BR provides
potent protection in an intestinal ischemia/reperfusion injury model (94).
Interestingly, the A2BR plays a protective role at the acute phase of the lung injury
even in a mouse model of chronic lung disease. Studies described in the

75

previous chapter showed that ADA/A2BR double knockout mice exhibited
enhanced pulmonary damage and inflammation compared to ADA-deficient mice
(60). The predominant interface between acute damage and the organs is the
vascular endothelium. Neutrophil penetrate the endothelium following acute
damage and vascular endothelial cells create a potential endothelial barrier to
prevent neutrophil infiltration, loss of fluid and edema formation. All studies
described above revealed a critical role of the A2BR in attenuating vascular
leakage through endothelial paracellular barriers. Hence, loss of vascular barrier
function due to A2BR deficiency is responsible for the enhanced pulmonary
inflammation and damage in A2BR-/- mice following acute lung injuries.
The mechanism by which the A2BR prevents vascular leakage is unknown.
However, it has been proposed that signaling pathways through cAMP,
subsequent

phosphorylation

of

VE-cadherin

and

vasodilator-stimulated

phosphoprotein, and alterations in cellular cytoskeleton are responsible for the
enhanced vascular barrier function (3, 68, 95, 96). In addition, a recent study
revealed that the neuronal guidance molecule netrin-1 can engage the A2BR on
neutrophils, providing an unexpected mechanism by which the A2BR may play a
protective role (97). More studies are needed to further investigate how the A2BR
plays a protective role in maintaining vascular integrity.
In contrast to the IT bleomycin model where bleomycin was exposed
directly to the lung, the IP bleomycin model involved 8 doses of bleomycin
treatments into the peritoneal cavity. Only mild acute injury occurred in this model
and we did not observe extensive pulmonary neutrophillia throughout the
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protocol. An acute phase inflammatory response was not as robust in this model
as that in the IT bleomycin model. In addition, although there was still vascular
damage and increased vascular permeability after bleomycin treatments at the
early stage, vascular barrier function was not a determinant factor in preventing
inflammation and damage in the lung. Mice did develop fibrosis in the lung and
pulmonary fibrosis was assessed on Day 33. A2BR-/- mice showed diminished
pulmonary fibrosis compared to wild type mice, suggesting the A2BR is playing a
pro-fibrotic role. This finding suggests that the A2BR only helps in maintaining
vascular integrity when an acute damage is involved; it plays a pro-fibrotic role at
the chronic stage of the diseases.
The observation in the IP bleomycin model is consistent with the findings
in A2BR antagonism study in ADA-deficient mice, where a pro-fibrotic and tissuedestructive role of the A2BR was revealed (57). Numerous studies support the
A2BR’s detrimental roles. The activation of the A2BR promotes fibroblasts
differentiation into myofibroblasts and hence promotes collagen production and
deposition (30). The engagement of the A2BR on human mast cells mediates the
expression of various pro-inflammatory cytokines such as IL-4, IL-8 and IL-13
(52, 55, 56, 98, 99). A2BR activation up-regulates the production of IL-6 from
mouse macrophages (75). These findings implicate a detrimental effect of the
A2BR in promoting the damage and injury at the chronic stage of the disease.
In conclusion, the results of the present study demonstrate that A2BR plays
a protective role in maintaining the integrity of vascular barrier when an acute
injury is involved. On the other hand, the activation of A2BR promotes the
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production of pro-fibrotic cytokines and chemokines and it plays a pro-fibrotic and
tissue-destructive role at the chronic stage of the disease. As a result, adenosine
and the A2BR regulate both the protective and detrimental aspects in diseases.
A2BR antagonist could be beneficial in treating chronic lung disease, especially at
the later stages; A2BR agonist could be useful in treating patients with acute
respiratory distress and protecting the vascular barrier. Further studies are
needed to understand the status of adenosine metabolism and A2BR signaling in
specific patients of these diseases in order to design adenosine-based therapies
to treat these patients. This will be the focus of the next chapter.
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CHAPTER 5
ALTERATIONS OF ADENOSINE METABOLISM
AND SIGNALING IN PATIENTS WITH CHRONIC
OBSTRUCTIVE PULMONARY DISEASE AND
IDOPATHIC PULMONARY FIBROSIS

Findings in the previous chapters suggest that the A2BR plays a protective
role in acute lung injury but a destructive role in chronic lung diseases. It is
critical to better understand adenosine metabolism and signaling in each specific
disease in order to design potential adenosine-based therapeutics. Studies
described in this chapter focus on investigating adenosine metabolism and
signaling, specifically A2BR signaling, in two types of human chronic lung
diseases.

INTRODUCTION
Adenosine and Human Chronic Lung Disease
The production of adenosine in the lungs of asthmatics and COPD
patients suggests that it may regulate aspects of lung disease (1, 100). There is
substantial clinical and scientific evidence to support this hypothesis. Adenosine
can directly influence cellular and physiological processes in the lungs of
asthmatics and patients with COPD (24, 100). For example, exogenous
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adenosine can elicit acute bronchoconstriction in patients with asthma or COPD
(101, 102), while no effect was found on normal individuals, suggesting a
fundamental difference regarding adenosine signaling in these patients. Receptor
binding studies to analyze adenosine receptor expression revealed the
significantly decreased affinity of the A1R, A2AR, and A3R in patients with COPD
compared with controls, whereas increases in density was observed. The density
of A2BR was decreased in patients with COPD compared with the control group,
but the affinity was not altered (103). The signaling pathways of adenosine can
influence the activity of multiple cell types that play a critical role in chronic lung
disease including, mast cells (104), eosinophils (35), macrophages (105),
epithelial cells (36), fibroblasts (30), and smooth muscle cells (106). Recent
studies directly implicate adenosine in the regulation of pulmonary fibrosis.
Exposure of human pulmonary fibroblasts to adenosine promotes differentiation
into myofibroblasts through mechanism that involved the A2BR (30). Moreover,
A2BR engagement promotes the production of fibronectin from type II epithelial
cells (107), a process that can impact pulmonary fibrosis. Lastly, it has been
shown that the expression levels of A2BR are elevated in remodeled airway
epithelial cells when comparing rapidly progressing idiopathic pulmonary fibrosis
patients to slowly progressing patients (108). Collectively, these studies
demonstrate that adenosine can regulate processes that influence pulmonary
fibrosis.
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Purinergic Remodeling in Animals Models of Chronic Lung Disease
Examination of adenosine levels in animal models of chronic lung disease
support these findings in humans. Transgenic mice that over express the TH2
cytokines IL-4 or IL-13 in the lungs develop progressive pulmonary inflammation
and injury characterized by eosinophilic and monocytic infiltrates, airway fibrosis
and alveolar airspace destruction in association with increases of adenosine
levels in the lungs (66, 109). In addition, adenosine levels are elevated in the
lungs of mice exposed to the fibrosis inducing agent bleomycin (110) or following
chronic ovalbumin exposure (111). Lastly, there are correlations between the
degree of inflammation and damage and adenosine accumulations in ADAdeficient mice (47). Therapeutic strategies to lower adenosine levels or disrupt
adenosine receptors lead to improvement in pulmonary pathologies in these
models. We have made the observation that the levels of key components of
adenosine metabolism and signaling are altered in these mouse models where
adenosine-based therapeutics are most effective. These changes include a
selective down-regulation of ADA, the major enzyme for adenosine metabolism,
the up-regulation of ecto-5’-nucleotidase (CD73), the major enzyme of adenosine
production, the down-regulation of adenosinie kinase (AK) and equilibrative
nucleoside transporters (ENT) (Figure 1). In addition, we have observed upregulation of pro-inflammatory and pro-fibrotic adenosine receptors in these
models (47, 66, 109, 110). This is a process we call purinergic remodeling.
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Experimental Rational and Goals
These findings raise the possibility that adenosine-based therapeutics may be
beneficial in the treatment of chronic lung disease such as COPD and IPF. If
changes in purinergic metabolism and signaling also exist in humans with COPD
and IPF, it would provide proof of concept information that these disorders may
benefit from adenosine-based therapeutics. The focus of the study described in
this chapter was to utilize tissues and from the Lung Tissue Research
Consortium (LTRC) to determine if “purinergic remodeling” exsits in patients with
COPD and/or IPF. Patients were classified as Stage 0 COPD, Stage 4 COPD,
Mild IPF and severe IPF according to spirometry, pathological specimen and high
resolution CT scan (Figure 5.1). Our hypothesis was that purinergic metabolism
and signaling components are altered in a manner that promotes adenosine
production in tissue samples from patients with COPD and IPF. Our results
demonstrate that CD73 and the A2BR are elevated in lung biopsy samples from
patients with Stage 4 COPD and Severe IPF compared to patients with
preserved lung function. This was associated with significant alterations in
expressions of pro-inflammatory mediators known to be driven by A2BR signaling
in animal models, and ex vivo studies demonstrated that activation of the A2BR
can influence the production of key inflammatory and fibrotic mediators from
macrophages isolated from these patients. This study provides novel and
important information into the potential involvement of adenosine signaling in
human chronic lung diseases, and provides insight into potential mechanisms for
screening patients for trials in adenosine-based therapies.
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Transcript Levels of Components of Adenosine Metabolism and Signaling
Are Altered in the Lungs of COPD and IPF Patients
Components of adenosine metabolism and signaling are altered in mouse
models of chronic lung disease in association with elevated levels of adenosine
(47, 66, 109, 110). Total RNA was isolated from lung biopsy specimens and realtime RT-PCR was performed to quantify key components of adenosine
metabolism and signaling. Results demonstrated a 3 fold increase of CD73
transcripts in whole lung RNA extracts from Severe IPF and Stage 4 COPD
patients compared to Mild IPF and Stage 0 COPD patients with preserved lung
function (Figure 5.2A). However, the transcript levels of ADA, AK and ENT1 were
not altered in Severe IPF and Stage 4 COPD patients (Figure 5.2, B-D). All four
adenosine receptors were detectable in subjects with preserved lung function
(Figure 5.2E). Transcript levels for the A2BR were significantly increased in
Severe IPF and Stage 4 COPD patients (Figure 5.2E). These findings
demonstrate elevations in components of adenosine production and A2BR
signaling in the lungs of patients with progressive chronic lung disease.

CD73 and ADA enzymatic activities are altered in the lungs of COPD and
IPF patients
To examine alterations in enzymatic activities of the key enzymes of
adenosine metabolism, protein extracts were made from lung biopsy specimens
and enzymatic activities of CD73 and ADA were quantified using HPLC (Figure
5.3). The enzymatic activity of CD73 was increased by 2 fold and 2.5 fold,
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Figure 5.1
Lung histopathology and high-resolution CT scans. Representative H&E staining
and hign-resolution CT scan images showing: (A) A Stage 0 COPD patient with
preserved lung function. (B) A Mild IPF patient with preserved lung function. (C) A
Stage 4 COPD patient. (D) A Severe IPF patient. Sections are representative of
10-14 different patients from each group.
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Figure 5.2
Expression of components of adenosine metabolism and signaling. Transcript
levels of various enzymes in adenosine metabolism, and adenosine receptors
were quantified in lung RNA extracts from patients using quantitative RT-PCR.
Shown are levels of (A) CD73, (B) ADA, (C) AK, (D) ENT1, (E) Adenosine
RESULTS
receptors. Results are presented as mean percentage of 18sRNA transcripts ±
SEM. *p ≤ 0.05 versus Mild IPF. # p ≤ 0.05 versus Stage 0 COPD. n = 4 (Stage 0
COPD), n = 10 (Mild IPF), n = 8 (Severe IPF and Stage 4 COPD).
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A

B

Figure 5.3
Determination of enzyme activity and representative chromatograms. (A) CD73
enzyme activity. Adenosine was quantitated by reverse phase HPLC, measuring
absorbance at 260nm. Chromatogram in the upper panel represents a typical curve
from a nucleotidase assay. The AMP peak is seen at 8 min, with adenosine detection
at around 13 min. Samples that have been preincubated with the enzyme inhibitor or
heat inactivated were used as controls (middle and lower panel). (B) ADA enzyme
activity. Inosine was quantitated by reverse phase HPLC, measuring absorbance at
260nm. Chromatogram in the up panel represents a typical curve from an ADA assay.
The Adenosine peak is seen at 13 min, with inosine detection at around 10 min.
Samples that have been heat inactivated were used as controls (lower panel).
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Figure 5.4
CD73 and ADA enzymatic activity. CD73 (A) and ADA (B) enzyme activity were
quantified in lung protein extracts from patients. Reaction mixtures were
separated, identified, and quantified by HPLC. Data are presented as mean
nanomoles of substrate converted to product per min per milligram of protein ±
SEM. *p ≤ 0.05 versus Mild IPF. # p ≤ 0.05 versus Stage 0 COPD. n = 4 (Stage 0
COPD), n = 10 (Mild IPF), n = 8 (Severe IPF and Stage 4 COPD).
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respectively, in Stage 4 COPD and Severe IPF patients compared to subjects
with preserved lung function (Figure 5.4A). This finding is consistent with
increased CD73 RNA levels and suggests that its expression is altered to
promote adenosine generation in patients with severe chronic lung disease.
There was a significant decrease in ADA enzymatic activity in Severe IPF
patients and Stage 4 COPD patients compared to subjects with preserved lung
function (Figure 5.4B). These observations also suggest that purinergic
remodeling exist in these patients and it promotes adenosine elevations.

Cellular localization of CD73 and A2BR expression in lung tissue from
COPD and IPF patients
To identify the cellular localization of key components of adenosine
metabolism and signaling in normal and diseased subjects, tissue sections were
stained with antibodies against CD73 and A2BR. In Mild IPF and Stage 0 COPD
subjects with normal lung function, CD73 was expressed on inflammatory cells
as well as endothelial cells (Figure 5.5, A and B). In Stage 4 COPD patients,
CD73 was expressed on inflammatory cells and endothelial cells (Figure 5.5C,
arrow). In Severe IPF patients, CD73 was localized to inflammatory cells,
endothelial cells and remodeled airway epithelial cells (Figure 5.5D, arrow).
A2BRs were localized on inflammatory cells, mostly macrophages in both Stage 0
and Stage 4 COPD patients (Figure 5.6, A and C). In IPF patients, A2BRs were
expressed on inflammatory cells and stromal cells (Figure 5.6, B and D) as well
as hyperplastic cells in remodeled airways (Figure 5.6F).
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Figure 5.5
Localization of CD73. Lung sections were stained with antibodies against CD73.
(A) Lung section from a Stage 0 COPD patient. (B) Lung section from a Mild IPF
patient. (C) Lung section from a Stage 4 COPD patient. (D) Lung section from a
Severe IPF patient. Sections are representative of 10-14 different patients from
each group. Scale bars=100 μm. (E) CD73 positive inflammatory cells were
quantified in 20 images. Data are presented as mean number of positive cells
per 10X field ± SEM. *p ≤ 0.05 versus Stage 0 COPD. #p ≤ 0.05 versus Mild IPF.
n = 4 (Stage 0 COPD and Mild IPF), n = 8 (Stage 4 COPD and Severe IPF).
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Figure 5.6
Localization of the A2BR. Lung sections were stained with antibodies against the
A2BR. (A) Lung section from a Stage 0 COPD patient. (B) Lung section from a
Mild IPF patient. (C) Lung section from a Stage 4 COPD patient. (D) Lung
section from a Severe IPF patient. Sections are representative of 10-14 different
patients from each group. Scale bars=100 μm. (E) A2BR positive inflammatory
cells were quantified in 20 images. (F) Lung section from an IPF patient. Data are
presented as mean number of positive cells per 10X field ± SEM. *p ≤ 0.05 versus
Stage 0 COPD. #p ≤ 0.05 versus Mild IPF. n = 4 (Stage 0 COPD and Mild IPF), n
= 8 (Stage 4 COPD and Severe IPF).
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Figure 5.7
Expression of CD73 and the A2BR in M2 macrophages. Lung sections from COPD
or IPF patients were reacted with antibodies against CD73 (A, green) or the A2BR
(B, green) together with the M2 macrophage marker CD206 (red). In the merged
images, yellow represents co-localization of CD73 or the A2BR and the M2 marker,
blue is dapi stained nuclei. Sections are representative of 10-14 different patients
from each group. Scale bars=100 μm.
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Alternatively activated macrophages, known as M2 macrophages, are
involved in microenvironments with prolonged inflammation and fibrosis (112,
113). To determine if M2 macrophages express CD73 and the A2BR, colocalization studies using an M2 macrophage marker, CD206 and CD73 or A2BR
antibodies

were

conducted

on

sections

from

these

patients.

Results

demonstrated that M2 macrophages express high levels of CD73 (Figure 5.7A)
and A2BR (Figure 5.7B) in Stage 4 COPD and Severe IPF patients.

Transcript levels of pro-inflammatory mediators downstream of adenosine
signaling are altered in the lungs of COPD and IPF patients
Adenosine A2BR signaling has been shown to regulate the expression of
certain inflammatory and fibrotic mediators in cell types and lung tissue
associated with chronic lung disease (53, 56-58, 70, 75). Total RNA was isolated
from lung biopsy specimens and real time RT-PCR was performed to quantify
key mediators that have been shown to be regulated by A2BR signaling. Results
demonstrate that transcript levels of IL-6, IL-8 and osteopontin are all increased
in both Stage 4 COPD and Severe IPF patients compared to subjects with
normal lung function (Figure 5.8, A-C). These findings suggest that the
expression of these pro-inflammatory and pro-fibrotic mediators that might be
regulated by A2BR signaling is elevated in these patients.
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Figure 5.8
Expression of pro-inflammatory mediators. Transcript levels of various cytokines
and chemokines were quantified in lung RNA extracts from patients using
quantitative RT-PCR. Shown are levels of (A) IL-6, (B) IL-8, (C) OPN. Results
are presented as mean percentage of 18sRNA transcripts ± SEM. *p ≤ 0.05
versus Mild IPF. # p ≤ 0.05 versus Stage 0 COPD. n = 4 (Stage 0 COPD), n = 10
(Mild IPF), n = 8 (Severe IPF and Stage 4 COPD).
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Figure 5.9
Associations between the expression of CD73, A2BR and inflammatory mediators.
The transcript levels of CD73 in individual COPD and IPF patients were
significantly associated with transcript levels of the A2BR (A). In IPF patients, the
transcript levels of IL-6 (B) and IL-8 (C) were significantly correlated with the
transcript levels of CD73; the transcript levels of IL-8 (D) and OPN (E) were
significantly correlated with the transcript levels of A2BR.
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Correlations

between

the

transcript

levels

of

A2BR,

CD73,

and

inflammatory/fibrotic mediators
To investigate the associations between CD73, the A2BR and mediators,
correlations were determined using linear regression. Among all the subjects
analyzed, the transcript levels of CD73 significantly correlated with the transcript
levels of A2BR (Figure 5.9A). Although significant correlations were not found in
COPD patients, in IPF patients, the transcript levels of IL-6 and IL-8 significantly
correlated with the transcript levels of CD73 (Figure 5.9, B and C); and the
transcript levels of IL-8 and OPN significantly correlate with the transcript level of
A2BR (Figure 5.9, D and E).

A2BR Signaling in M2 macrophages contributes to the production of IL-8
and IL-6
To determine if the A2BR on M2 macrophages is directly involved in the
induction of pro-inflammatory/fibrotic mediators, human primary alveolar
macrophages were isolated from the BAL fluid of Severe IPF and Stage 4 COPD
patients. Co-localization studies using an M2 macrophage marker, CD206 and
either CD73 or A2BR antibodies were conducted on cells of an IPF patient.
Results demonstrated that the macrophages were M2 macrophages, which
expressed both CD73 and the A2BR (Figure 5.10A). Primary alveolar
macrophages were then pretreated with an A2BR antagonist (CVT-6883) before
NECA exposure. This resulted in a loss of NECA-stimulated increases in IL-8
and IL-6 protein levels in the media (Figure 5.10B). Interestingly, A2BR inhibition
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Figure 5.10
A2BR-dependent IL-8 and IL-6 expression in human primary alveolar macrophages. (A)
Cells from an IPF patient were reacted with antibodies against CD73 (A, upper panel,
green) or the A2BR (A, lower panel, green) together with the M2 macrophage marker
CD206 (red). In the merged images, yellow represents co-localization of CD73 or the
A2BR and the M2 marker, blue is dapi stained nuclei. (B) ELISA measurements of IL-8
and IL-6 production from macrophage cultures of IPF and COPD patients. Results are
presented as mean concentrations of cytokines ± SEM. *p ≤ 0.05 versus cells without
any treatment. #p ≤ 0.05 versus cells treated with NECA alone. n = 6.
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Figure 5.11
A2BR-dependent IL-8 and IL-6 mRNA expression in human primary alveolar
macrophages from IPF patients. Real-time PCR measurements of IL-8 (A) and IL-6
(B) mRNA expression from macrophage cultures of IPF patients. Results are
presented as mean percentage of 18sRNA transcripts ± SEM.. *p ≤ 0.05 versus
cells without any treatment. #p ≤ 0.05 versus cells treated with NECA alone. n = 6.
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can decrease the base line production of IL-8 and IL-6 in cell cultures from the
IPF patient, suggesting these cells are already activated and adenosine
produced from these cells can activate the A2BR and contribute to IL-8 and IL-6
production (Figure 5.10B). Consistent to the levels of protein release into the
macrophage culture media from IPF patients, IL-8 and IL-6 mRNA levels are
altered in a similar pattern in response to NECA and/or CVT-6883 (Figure 5.11),
suggesting that A2BR signaling directly regulates gene transcription rather than
protein release. These findings demonstrate that IL-8 and IL-6 expression is
regulated by engagement of the A2BR on alveolar macrophages isolated from the
lungs of IPF and COPD patients.

DISCUSSION
Adenosine is a nucleoside and signaling molecule that is generated in
response to cell stress or damage. Substantial evidence indicates that there are
elevated adenosine levels in patients with chronic lung disease. Elevation of
adenosine levels were seen in BAL fluid collected from asthmatics (25), in the
exhaled breath condensate of patients with allergic asthma (114), in plasma in
asthmatic subjects following bronchial provocation with allergen (115), and
patients with exercise-induced asthma (116). In addition, elevated adenosine
levels have been found in sputum samples from patients with cystic fibrosis
(117). Consistent with that, elevated adenosine levels are found in various
mouse models exhibiting features of chronic lung disease (66, 109, 110),
suggesting adenosine is sufficient to access pathways that lead to the
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development of the features of chronic lung disease. In addition, the levels of key
components of adenosine metabolism and signaling are altered in these mouse
models to promote adenosine accumulation and tissue-destructive adenosine
receptor signaling, a process known as purinergic remodeling. Our hypothesis
was that purinergic remodeling also exists in patients with COPD and/or IPF.
This would provide direct evidence that chronic lung diseases such as COPD
and IPF may benefit from treatment with adenosine-based therapeutics.
CD73 is the major extracellular enzyme for adenosine production. CD73
levels were found to be up-regulated in the lungs of ADA-deficient mice and mice
exposed to bleomycin (47, 110). In addition, bronchial cultures from patients with
cystic fibrosis exhibited 3-fold higher CD73 activity than normal cultures (118).
These findings suggest that the up-regulation of CD73 is an important purinergic
remodeling response in lung where adenosine-dependent injury is present. In the
current study, we observed that the transcript levels of CD73 are elevated in both
Severe IPF and Stage 0 COPD patients compared with subjects with normal lung
functions. Consistent with this, the enzymatic activity of CD73 is significantly
increased in Severe IPF and Stage 4 COPD patients, suggesting there is an
increased capacity for adenosine production in these patients compared to
normal subjects. To localize CD73 in the lung, immunostaining showed CD73 is
expressed on endothelial cells, inflammatory cells in normal lungs and
endothelial cells, inflammatory cells and remodeled airway epithelial cells in
diseased lungs. This demonstrates that at the sites of inflammation and tissue
remodeling, there is excessive amounts of adenosine generated.
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ADA is the major adenosine metabolic enzyme that deaminates
adenosine to inosine both intracellularly and extracellularly. Mice over expressing
the TH2 cytokine IL-4 or IL-13 in their lungs showed down-regulated ADA
transcripts and enzymatic activity along with elevated lung adenosine levels and
severe pulmonary inflammation, fibrosis and alveolar destruction (66, 109).
Similar findings were observed in the lungs of mice treated with bleomycin (110).
Our findings suggest that although the transcript levels of ADA are not changed
in IPF and COPD patients, the enzymatic activity of ADA is significantly reduced
in Stage 4 COPD and Severe IPF patients compared to subjects with normal
lung function. Post-transcriptional regulations of ADA mRNA could contribute the
discrepancy between the transcript and protein levels of ADA. Nonetheless, there
seems to be less adenosine consumption, which could also contribute to higher
levels of adenosine compared to normal subjects.
Adenosine regulates numerous cellular activities by engaging cell surface
adenosine receptors. Work from our lab and others have provided evidence that
adenosine receptor expression is altered in models of lung disease. The A1R,
A2BR, A3R have been shown to be elevated in the lungs of models exhibiting
pulmonary fibrosis and alveolar destruction (48, 66, 109, 119). The A2AR, which
is down-regulated in these models, is thought to be largely an anti-inflammatory
receptor. The differential expression of these receptors in these models of lung
disease provides insight into the potential role of adenosine signaling in COPD
and pulmonary fibrosis. In the current study, although all four adenosine
receptors are detectable, the transcript level of the A2BR is the only adenosine
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receptor that is elevated in both Stage 4 COPD and Severe IPF patients
compared to subjects with normal function. This receptor is mostly localized on
inflammatory cells as well as lung stromal cells such as airway epithelial cells
and fibroblasts.
The A2BR has the lowest affinity for adenosine and is therefore likely
activated under pathological conditions where adenosine levels are increased.
A2BR activation has both anti-inflammatory and pro-inflammatory actions and
both pro- and anti-fibrotic roles (54). Despite the receptor’s homeostatic and
protective functions during the acute phase of lung injury (14, 58), several studies
in mouse models have shown that signaling through the A2BR can contribute to
the pathology and progressive nature of chronic lung diseases such as IPF and
COPD (30, 57, 70). Substantial evidence has indicated A2BR’s pro-fibrotic
functions. Studies have shown that engagement of the A2BR promotes their
differentiation of pulmonary fibroblasts into myofibroblasts and hence increases
the deposition of collagen and fibrosis (30). Engagement of the A2BR can
mediate the direct expression of pro-inflammatory cytokines such as IL-4, IL-8
and IL-13 from human HMC-1 cells (53, 55), IL-13 from mouse mast cells (56),
IL-6 and osteopontin from mouse macrophages (48, 57, 75). Consistent with
these findings, the transcript of levels of IL-6, IL-8 and osteopontin downstream
of A2BR signaling are elevated in both Severe IPF and Stage 4 COPD patients
compared to subjects with normal lung function. In IPF patients, the elevation of
these mediators is in close association with increases in A2BR and CD73. In
addition, we showed that treatment with a selective A2BR antagonist can prevent
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the release of IL-6 and IL-8 from macrophages isolated from Severe IPF or Stage
4 COPD patients. These findings suggest that indeed there is enhanced A2BR
signaling in these patients and the A2BR antagonist can be useful in treating
patients with IPF and COPD.
Substantial evidence in mouse models of chronic lung disease suggests
that adenosine-based therapeutics may be beneficial for the treatment of chronic
lung disease where alveolar destruction and fibrosis are prominent. ADA
replacement therapy consists of intra-peritoneal or intranasal treatment with ADA
conjugated to polyethylene glycol. This therapy is able to prevent elevations in
adenosine, or lower the levels of elevated adenosine in various models of lung
disease (45, 48, 66, 109). Preventing elevations in adenosine using this therapy
in ADA-deficient mice, IL-13 transgenic mice or IL-4 transgenic mice can prevent
and reverse TGF-β1 production and fibrosis in the lungs. In addition, lowering
adenosine levels in the lungs of mice treated with bleomycin leads to reduced
fibrosis in this model (unpublished data). Thus, adenosine elevations play a
direct role in accessing pathways that lead to alveolar airway destruction and
pulmonary fibrosis. The ADA-deficient model of adenosine-dependent pulmonary
disease has provided a useful mechanism for examining the contribution of
individual adenosine receptors to the inflammation and damage seen in the lung
in response to adenosine elevations. A recent study used a selective A2BR
antagonist (CVT-6883) to block the engagement of this receptor in ADA-deficient
mice. Treating ADA-deficient mice with this antagonist prevented the production
of numerous proteases and TGF-β1 from alveolar macrophages, thus preventing
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the development of alveolar airspace enlargement and pulmonary fibrosis (57).
Treatment with CVT-6883 also prevented pulmonary fibrosis in the bleomycin
induced fibrosis model (57). These finding demonstrate that elevations in
adenosine in the lung can promote airway enlargement and fibrosis in part by
engaging the A2BR. These findings in mouse models raised the possibility that
ADA replacement therapy and A2BR antagonist treatment may benefit patients
with COPD and pulmonary fibrosis.
A2BR signaling can have distinctive roles in different diseases. It serves a
tissue-protective role in acute lung injuries, whereas it plays a detrimental role in
chronic lung diseases. It would be helpful to understand adenosine metabolism
and signaling in each specific type of disease. Our findings in this chapter
suggest that adenosine metabolism and signaling components are altered in a
manner that promotes adenosine production in patients with COPD and IPF.
These changes include the up-regulation of CD73, a down-regulation of ADA
activity, and elevated in the A2BR. It provides proof of concept information that
human COPD and IPF patients may benefit from adenosine-based therapeutics.
In addition, these changes could help to predict patient populations, where
adenosine levels are elevated along with up-regulations of CD73, downregulations of ADA and enhanced A2BR signaling, may be suitable for therapies
such as ADA-replacement therapy and A2BR antagonist treatment.
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CHAPTER 6
OVERVIEW, FUTURE DIRECTIONS AND
CONCLUSION

Overview
Adenosine is a nucleoside signaling molecule produced in response to cell
stress or damage (120). By signaling through one of the four G-protein coupled
adenosine

receptors,

adenosine

can

influence

cellular

physiology

and

intracellular signaling pathways through a variety of mechanisms (52, 121, 122).
One of the most prominent areas of study is the effects of adenosine on immune
regulation. During acute tissue injury, elevated adenosine levels generally play
anti-inflammatory

and

tissue-protective

functions.

In

contrast,

sustained

adenosine elevations in persistent inflammatory conditions, including chronic
lung diseases such as IPF and COPD, appear to access tissue-destructive and
pro-inflammatory pathways. The differential activities of adenosine receptors
have been shown to contribute to the dichotomous role of adenosine. Among the
four adenosine receptors, the A2BR draws a lot of attention because it has the
lowest affinity for adenosine. Thus, it can be activated under pathological
conditions when adenosine levels are elevated and may play important roles in
disease. Work conducted in this dissertation was designed to better understand
the role of the A2BR in various acute and chronic aspects of pulmonary disorders.
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The ADA-deficient mouse model demonstrates that elevated levels of
adenosine in the mouse is sufficient to induce lung disease with many of the
pathological features seen in human chronic lung diseases, including pulmonary
inflammation, mucus hypersecretion, airspace enlargement, fibrosis and airway
remodeling. A previous study in our lab utilized this animal model and showed
that treatment with a selective A2BR antagonist results in decreased pulmonary
inflammation, alveolar destruction and pulmonary fibrosis, suggesting the A2BR is
playing a tissue-destructive and pro-fibrotic role. In Chapter 3 of this dissertation,
I took the genetic approach and deleted the A2BR gene from ADA-deficient mice
to further investigate the role of the A2BR. Surprisingly, ADA/A2BR double
knockout

mice

died

precociously

and

exhibited

enhanced

pulmonary

inflammation, airspace enlargement, mucus metaplasia and pulmonary fibrosis.
A major finding in this study was the enhanced vascular permeability in
ADA/A2BR double knockout mice compared to ADA-deficient mice. We concluded
that enhanced loss of vascular barrier function in mice lacking the A2BR is
associated with enhanced pulmonary neutrophilia and enhanced pulmonary
damage. Although the A2BR has been proven to have tissue-destructive
functions, it thus appeared to also play an important protective role at early stage
of the disease in the ADA-deficient model.
In Chapter 4 of this dissertation, I sought to further address the concept of
A2BR’s bi-phasic functions. Two bleomycin-induced pulmonary fibrosis models
were utilized to investigate the A2BR’s distinctive functions at different stages of
the disease. The IT bleomycin model involves a single bleomycin exposure
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directly into the trachea and this local delivery is associated with acute damage
to the lung. When A2BR-/- mice were exposed to bleomycin IT, enhanced loss of
endothelial barrier function during the early stages of the pulmonary injury
resulted in enhanced neutrophil infiltration into the lung and enhanced pulmonary
damage. This acute inflammation counteracted the pro-fibrotic effect of the A2BR
so A2BR-/- mice were not protected from bleomycin-induced pulmonary fibrosis. In
contrast, the IP bleomycin model does not involve extensive acute lung damage
or inflammation, and in this case, A2BR-/- mice were protected from bleomycininduced pulmonary fibrosis. These results demonstrate that the A2BR plays a
protective role in attenuating vascular leakage at the acute phase of the disease,
whereas it exhibits pro-inflammatory and pro-fibrotic roles in chronic lung
diseases. These findings highlight the complexity of A2BR signaling and suggest
that it would be critical to investigate the status of A2BR in specific diseases.
In different mouse models of pulmonary fibrosis, molecules involved in
adenosine metabolism and signaling are altered to promote adenosine
production (22, 66, 109-111, 123, 124). In Chapter 5 of this dissertation, human
samples from IPF and COPD patients were utilized to examine the status of
adenosine metabolism and signaling to determine if these changes exist in
human chronic lung diseases. Findings suggested that components of adenosine
metabolism and signaling are altered in a manner that promotes adenosine
production in patients with COPD and IPF. These changes included the upregulation of CD73, a down-regulation of ADA activity, and elevated A2BR
expression. In addition, mediators that are regulated by the A2BR, such as IL-6,
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IL-8 and osteopontin were elevated in these samples and activation of the A2BR
on macrophages isolated from the airways of COPD and IPF patients was shown
to directly induce the production of these mediators. This study provides proof of
concept information that A2BR signaling can promote the production of
inflammatory and fibrotic mediators in patients with these disorders and these
disorders may benefit from adenosine-based therapeutics such as exogenous
ADA enzyme therapy or A2BR antagonist treatment.
Various studies in cellular and animal models provide substantial evidence
that adenosine signaling through adenosine receptors can serve both protective
and detrimental roles (90) (Figure 6.1). Adenosine and A2BR’s tissue-protective
role partially comes from its role in the maintenance of pulmonary barrier function
(3, 14, 15). In lung injuries where the damage to the lung is accompanied by
disruption of endothelial barriers, the A2BR plays an important role in maintaining
vascular endothelial cell junctions and creating a potential endothelial barrier to
prevent neutrophil infiltration. Studies described in this dissertation revealed a
critical protective role of the A2BR in attenuating vascular leakage through
endothelial paracellular barriers. In addition, A2BR signaling may also promote
the normal function of CFTR, contribute to the maintenance of airway surface
liquid height in airway epithelial cells, and prevent mucus stasis in the airways.
The local cytokine milieu in different diseases may play an important role
in regulating the anti- or pro-inflammatory actions of adenosine. Acute lung
injuries are associated with elevations in IL-12, IFNγ and TNFα and a TH1
dominated environment. Adenosine signaling usually serves to down-regulate the
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production of TH1 cytokines (125). In contrast, a lot of chronic lung diseases
such as asthma, COPD, and interstitial lung diseases are associated with
elevations in TH2 cytokines such as IL-4, IL-5, IL-8 and IL-13 (2). Adenosine
acting through the low affinity A2BR can increase the production of TH2 cytokines
from various cell types (53, 55, 56, 99) (Figure 6.1). In mast cells, A2BR activation
can stimulate the production of the TH2 cytokines that regulate both airway
constriction and inflammation. In addition, the A2BR can promote the production
of mediators from macrophages. Previous studies have shown that A2BR
activation stimulates the production of IL-6 and osteopontin from mouse
macrophages (126). My result was the first evidence to show it can also promote
the production of IL-6 and IL-8 from human alveolar macrophages. Furthermore,
activation of the A2BR on fibroblasts promotes the release of IL-6 and stimulates
the differentiation into myofibroblasts (30), which play a key role in the production
of extracellular matrix and fibrotic remodeling. These findings suggest that
adenosine signaling is detrimental and can contribute to the amplification or
progression of chronic lung disease
Taken together, patients with either acute lung injury or chronic lung
disease may both benefit from adenosine-based therapeutics. Compounds
selectively

targeting

adenosine

receptors

are

under

development

by

pharmaceutical companies. For example, The selective A2BR antagonist, CVT6883 has completed phase I clinical trials with no adverse events reported (127);
however, efficacy in phase II trials has not yet been shown. Due to the
complication of adenosine receptor signaling in different aspects and at the
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different stages of the disease, the development of adenosine-based
therapeutics can be challenging. It is critical to determine the right adenosine
receptor as the drug target, whether to activate or inhibit it in any particular type
of disease. Moreover, the dosage and timing of the drug exposure can also be a
determinant factor in order to prevent any unwanted side effects. In acute lung
injuries where a TH1 environment is commonly involved, the A2BR plays a critical
role in maintaining vascular barrier function; when these patients fail the wound
healing response and develop chronic lung diseases, A2BR signaling promotes
the release of pro-inflammatory cytokines and contributes to disease progression
(Figure 6.2).
My findings in this dissertation suggest that A2BR agonist could be useful
in treating patients with acute lung injuries; whereas A2BR antagonist can be
used to treat chronic lung diseases. Timing of these treatments can be critical.
A2BR agonist to treat acute lung injuries may only be beneficial at the acute
phase of the disease; A2BR antagonist to treat chronic lung disease may only be
effective at the late stage of the disease, whereas treatment early in the disease
may cause vascular leakage and enhanced injury. In addition, my findings
provide a novel method to identify the subset of patients with chronic lung
disease that may benefit from adenosine-based therapeutics. It would be helpful
to conduct bronchoscopy on patients with IPF or COPD, isolate alveolar
macrophages and determine if the production of pro-inflammatory cytokines from
these macrophages respond to A2BR agonist or antagonist. If macrophages
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Figure 6.1
A2BR activities in pulmonary cells. Adenosine signaling through the A2BR can
promote endothelial barrier function and serve important anti-inflammatory and
tissue-protective roles. A2BR signaling also contributes to the maintenance of
ASL height in airway epithelial cells. In contrast, the A2BR contributes to the
production of IL-8, IL-4, IL-13, and VEGF from mast cells. A2BR engagement
can also promote the production of osteopontin, IL-6, and IL-8 from
macrophages; IL-6 release from fibroblasts and myofibroblasts differentiation.
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Figure 6.2
Model of A2BR signaling in acute and chronic lung disease. In acute injury,
adenosine and the A2BR can serve important anti-inflammatory and protective
roles, such as inhibition of Th1 cytokine production and maintenance of
vascular barrier function. In chronic lung disease, A2BR signaling contributes to
the production of Th2 cytokines and promotes the activity of effecter cells such
as mast cells, macrophages and fibroblasts that can drive disease progression.
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isolated from the patients express high levels of A2BR and the production of IL-8
and IL-6 from these cells can be promoted by A2BR agonist treatment and
inhibited by A2BR antagonist treatment, it is very likely that these patients would
benefit from exogenous ADA enzyme therapy or A2BR antagonists. Additional
studies are needed to further investigate the specific mechanisms involved in
adenosine signaling in various pulmonary disorders.

Future Directions
Treatment of ADA-Deficient Mice with A2BR Agonists
We have provided substantial evidence that the A2BR plays a protective
role during the early stage of pulmonary injury when acute inflammation is
involved, and a tissue-destructive/pro-fibrotic role during the chronic stage of the
disease. Another direct way to verify this concept is to treat ADA-deficient mice
with an A2BR agonist at different stages of the disease. A selective A2BR agonist
BAY60-6583 is available from Bayer HealthCare. Treating ADA-deficient mice
from birth with this compound may postpone the development of pulmonary
phenotypes. However, if ADA-deficient mice are kept on PEG-ADA from birth till
Day 21, and then treated with the A2BR agonist a week after the last PEG-ADA
treatment, we may observe precocious injury and death of these animals
compared to animals without the agonist treatment. Similarly, this method could
be utilized in other models of chronic lung disease such as the bleomycininduced pulmonary fibrosis model. These studies would raise the possibility that
A2BR agonist could be used to treat diseases during acute phases.
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Timing and Dosage of A2BR Antagonist Treatment
Previous studies have shown that the treatment with the selective A2BR
antagonist, CVT-6883, resulted in diminished pulmonary inflammation and
damage in ADA-deficient mice and decreased pulmonary fibrosis in the model of
IT bleomycin-induced pulmonary fibrosis. These results suggest that the A2BR
plays a pro-inflammatory and pro-fibrotic role in these models. Notably in
previous studies, the treatment of the A2BR antagonist did not start and the
receptors were not blocked until the disease status had been established. In
addition, other studies, and the findings in this dissertation, support a tissueprotective role of the A2BR during the acute stage of the disease. It would be
helpful to treat these animal models with the A2BR antagonist from birth and
determine if it could mimic the conditions of A2BR gene deletion. It is possible that
although treatment of the antagonist later would improve pulmonary phenotypes,
treatment from birth may accelerate the development of the pulmonary damage
in these animals.
A discrepancy between pharmacological inhibition and genetic knockout is
that the receptor’s activity may not be totally inhibited with antagonist treatment,
while genetic knockout absolutely abolishes the receptor’s activity. Thus, genetic
deletion may result in loss of homeostatic roles of the receptor that would not be
revealed by pharmacological inhibition. It will be important to determine the
dosage of the antagonist that is sufficient to block the tissue-destructive and profibrotic role of this receptor, but conserves the homeostatic and tissue-protective
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role. This could be done by treating animal models with different doses of the
antagonist and monitoring the down-stream signaling pathways of the A2BR, such
as cAMP levels, change of vascular permeability and gene transcription profiles.

A2BR Signaling and Mucociliary Clearance
Previous studies have shown that the A2BR is an important regulator of
cystic fibrosis transmembrane conductance regulator (CFTR) functions, and
lacking this receptor may lead to dehydration of airway surface liquid volume and
mucus stasis (74). Thus, A2BRs are required for airway surface liquid (ASL)
volume homeostasis and mucus clearance in the airways. This is consistent with
our findings that there is enhanced mucus metaplasia in ADA/A2BR double
knockout mice compared to ADA-deficient mice even though mucin gene
transcription is decreased. Studies conducted with epithelial cells ex vivo would
provide us a simplified system to investigate the A2BR signaling pathway in
airway epithelial cells. A standard protocol could be used to isolate mouse
primary tracheal epithelial cells from wild type and A2BR-/- mice and it would be
helpful to compare airway surface liquid height, mucin gene expression, mucus
production and secretion.
Mouse tracheal epithelial cells from wild type and A2BR-/- mice could be
isolated and grown on transwells coated with rat tail collagen. Cells could then be
maintained for at least 14 days to allow the differentiation and the formation of
air-liquid interface. β-tubulin staining will be performed on cells from wild type and
A2BR-/- mice to compare the number of ciliated cells that contribute to mucus
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clearance. Airway surface liquid height will be determined by confocal
microscopy. 10 ng/ml IL-13 could be used to treat tracheal epithelial cells to
induce mucus metaplasia. Comparisons of mucus production and secretion
between cells from wild type and A2BR-/- mice could be done by histological
analysis

(mucus

staining),

real-time

RT-PCR

analysis

of

mucin

gene

transcription, and mucus contents in apical and basolateral media after the
treatment. NECA, an A2BR agonist could be used to treat epithelial cells after IL13 stimulation to determine the functions of A2BR signaling and mucus secretion.
I expect that tracheal epithelial cells isolated from A2BR-/- mice will have
fewer ciliated cells and collapsed airway surface liquid height. Both of these will
contribute to diminished mucus clearance and enhanced mucus deposition on
airway epithelium. IL-13 treatment will induce mucus metaplasia in wild type and
A2BR-/- tracheal epithelial cells. Although the same levels of mucus production are
found in both genotypes, there may be a significant decrease in mucus secretion
in the apical media of cells isolated A2BR-/- mice, suggesting a mucus secretion
defect of airway epithelial cells lacking the A2BR. A2BR activation by NECA will
enhance mucus secretion only in wild type epithelial cells but not in A2BR-/- cells.
These expected results will demonstrate that the A2BR is important in maintaining
airway surface liquid height, differentiation of ciliated epithelial cells, and mucus
secretion.
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Purinergic Remodeling in Normal Subjects in Comparison to Diseased
Patients
A major limitation to the study described in Chapter 5 of this dissertation is
the lack of normal subjects in comparison to subjects with IPF and COPD.
Although we concluded that adenosine metabolism and signaling in patients of
IPF and COPD are altered to promote adenosine production, comparisons were
done between Severe IPF versus Mild IPF, and Stage 4 COPD versus Stage 0
COPD. Moreover, our ex vivo experiments showing A2BR activation can directly
regulate IL-6 and IL-8 production were performed with cells isolated from Severe
IPF or Stage 4 COPD patients. A more definitive approach would be to
characterize purinergic remodeling using frozen tissue and tissue sections, and
to isolate alveolar macrophages from normal subjects. I expect that the levels of
CD73, ADA and A2BR would be altered more dramatically in diseased subjects
when compared to normal subjects. Levels of other enzymes and molecules in
adenosine metabolism and signaling that did not change in the previous study
may also be altered. In the ex vivo experiment, macrophages isolated from
normal subjects are not activated, thus they do not express high levels of A2BR.
Baseline levels of IL-6 and IL-8 in media of these cells are lower than that of
activated macrophages from diseased patients. NECA stimulation may change
the characteristics of these cells, including the induction of M2 macrophage
activation,

A2BR

expression

and

production

of

pro-inflammatory/fibrotic

mediators.
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Adenosine Production in M2 Macrophages
An interesting finding in the ex vivo experiment using primary
macrophages is that the macrophages isolated from Severe IPF and Stage 4
COPD patients are already activated and they release high levels of IL-6 and IL-8
at base line. The A2BR antagonist treatment can significantly decrease the
release of these mediators. Moreover, these macrophages express the M2
macrophage marker CD206 and they also express CD73. These findings
suggest that CD73 in these cells is enzymatically active and adenosine is
generated at base line. It would be helpful to verify the activity of CD73 by adding
the inhibitor of CD73, AoPCP, into the cell culture. I expect that the inhibition of
CD73 would decrease the release of IL-6 and IL-8 at base line, suggesting that
adenosine is produced from M2 macrophages and it can engage A2BR to play a
pro-inflammatory role.

Conclusion
Extensive analysis of inflammation, alveolar destruction, and fibrosis in
mouse models suggest that adenosine based therapeutics such as ADA enzyme
therapy and A2BR antagonism would be beneficial in the treatment of human
conditions such as COPD and IPF. Understanding the involvement of A2BR
signaling pathways will provide novel and important information into the potential
significance of adenosine signaling in human lung disease, as well as provide
insight into potential mechanisms for screening patients for potential adenosinebased therapeutics that are currently being planned. The findings in this
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dissertation suggest that the A2BR is playing a homeostatic and protective role
during the acute stage of lung injury; while it plays a pro-fibrotic and tissuedestructive function during the chronic stage of the disease. As a result, patients
with acute lung injuries or chronic lung diseases can both benefit from adenosine
and A2BR-based therapeutics. However, the A2BR may have a bi-phasic effect on
inflammation and fibrosis and cautions must be taken when designing A2BR
agonist to treat patients with acute lung injuries, or A2BR antagonist to treat
human chronic lung diseases. For example, the A2BR antagonist could be
beneficial in treating patients with chronic lung diseases only when it is given
after the disease status is established. Additional studies in models as well as
clinical trials are needed to investigate the roles of adenosine and adenosine
receptors in each particular disease, and the efficacy of new generations of
adenosine receptor agonists and antagonists in the treatment of acute and
chronic lung diseases.
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